Podcasts about Stardust

"You also want to deal with patient preferences. We do want to get their disease under control. We want to make them live a long, good quality of life. But do they want to come to the clinic once a week? Is it a far distance? Is geography a problem? Do they prefer not taking oral chemotherapies at home? We have to think about what the patient's preferences are to some degree and kind of incorporate that in our decision-making plan for treatments for relapsed and refractory myeloma," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about multiple myeloma treatment considerations. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 6, 2027. Ann McNeill has disclosed a speakers bureau relationship with Pfizer. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of multiple myeloma. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 398: An Overview of Multiple Myeloma for Oncology Nurses Episode 395: Pharmacology 101: Monoclonal Antibodies Episode 372: Pharmacology 101: Proteasome Inhibitors ONS Voice articles: Effective Care Transitions Are Essential for New Multiple Myeloma Treatments New Multiple Myeloma Treatments Present New Challenges in Side Effect Management Reduce Racial Barriers and Care Inequities for Black and African American Patients With Multiple Myeloma ONS Voice FDA approval alerts ONS Voice oncology drug reference sheets: Belantamab mafodotin-blmf Daratumumab Motixafortide Selinexor Clinical Journal of Oncology Nursing articles: Journey of a Patient With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Oncology Nursing Forum article: Facilitators of Multiple Myeloma Treatment: A Qualitative Study ONS books: Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) Multiple Myeloma: A Textbook for Nurses (third edition) ONS course: ONS Hematopoietic Stem Cell Transplantation™ ONS Huddle Cards: Financial Toxicity Hematopoietic Stem Cell Transplantation (HSCT) Monoclonal Antibodies ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Society of Clinical Oncology (ASCO)–Ontario Health: Treatment of Multiple Myeloma Living Guideline International Myeloma Foundation: Clinical Trials Fact Sheets Clinical Trial Support Resource Library Multiple Myeloma Research Foundation resource: Treatments for Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Typically for our first-line therapies, we use certain classes of drugs and some of them are proteasome inhibitors like bortezomib and carfilzomib. We also have IMiDs or immunomodulatory agents like thalidomide, lenalidomide, and pomalidomide. We have monoclonal antibodies, anti-CD38 monoclonal antibodies. Of course, we can never talk about treatment for myeloma without mentioning dexamethasone. It is an integral part of our treatment regimen. Most of our frontline therapies now are not just a single agent. They're not even doublets anymore. Typically, they're triplet therapies. And now in 2026, it's leaning more toward quadruplet therapies. By that, I mean you're taking a proteasome inhibitor, an immunomodulatory drug, dexamethasone, and an anti-CD38 monoclonal antibody all together to present patients with a good chance their induction therapy will lead to a good chance of them responding to treatment." TS 4:25 "[With] myeloma labs, there should be some indication after each cycle of therapy that the treatment is working. So, you don't have to do a whole myeloma panel, but maybe getting a monoclonal protein spike, maybe getting a free light chain assay, or maybe an immunoglobulin G or immunoglobulin A level, just to see if the treatment is working. So, those labs are crucial to determine whether the therapies are working. And again, the lab improvements usually correlate with the clinical presentation of the patient." TS 11:01 "There are active clinical trials ongoing with drugs like cell mods. Cell mods are the new oral anticancer agents for myeloma that have shown great promise with efficacy and safety profiles. And then there are other combinations that are showing a lot of promise. So, drugs that are already approved by the U.S. Food and Drug Administration (FDA). And I'm talking about pairing anti-CD38 monoclonal antibodies with bispecific T-cell engagers. If you do that, there has been some evidence that these combinations are very efficacious and responses are durable. And there are ongoing clinical trials and studies being done right now to see if these can be FDA-approved to pinpoint where they are as far as in comparison to other treatments." TS 20:10 "I always tell patients to try to participate in safe, and I want to stress safe, physical activity. So, I tell patients, the more you sit on the couch or you sit in the chair for most of the day, that unfortunately will make your pain worse. So, trying to get up and about and doing some physical activity, such as getting a physical therapy evaluation and a treatment program, no matter how passive or mild or gentle it is, can really help these patients with bone pain." TS 26:10 "I think it's important to realize that myeloma has had amazing advances in science, research and treatments. I think that all of these things coming together, all the science and clinical trials and everything like that, has led to a significant increase in overall survival of our patients, which ultimately is a great thing. We want patients to live longer and they're living longer with a very good quality of life. So, I think it's important to realize that myeloma is very well studied, very well researched, and it's still ongoing with many, many clinical trials." TS 36:04

Generational WWE fumbles. Simon Miller presents 12 MORE Weird Periods WWE Icons Would Like You To Forget...ENJOY!Follow us on Twitter:@SimonMiller316@WhatCultureWWEFor more awesome content, check out: whatculture.com/wwe Hosted on Acast. See acast.com/privacy for more information.

"Radioimmunoconjugates work through a dual mechanism that combines immunologic targeting with localized radiation delivery. The monoclonal antibody components bind to specific tumor-associated antigens such as CD20, expressed on malignant B cells. Once found, the attached radioisotope delivers beta radiation directly to the tumor, causing DNA damage and cell death," Sabrina Enoch, MSN, RN, OCN®, CNMT, NMTCB (CT), theranostics clinical specialist at Highlands Oncology in Rogers, AR, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radioimmunoconjugates. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 30, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of radioimmunoconjugates in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 377: Creating and Implementing Radiopharmaceutical Policies and Procedures Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles ONS Voice articles: Interprofessional Collaboration Reduces Time to Neutropenia Antibiotic Administration Radiopharmaceuticals and Theranostics Offer New Options for Oncology Nurses to Transform Cancer Care Radiopharmaceuticals Pack a One-Two Punch Against Cancer Safety Is Key in Use of Radiopharmaceuticals Telehealth Has Value During Radiotherapy, Patients Say ONS Voice oncology drug reference sheets: Lutetium Lu 177 dotatate Lutetium Lu 177 vipivotide tetraxetan Radium 223 dichloride Sodium iodide-131 Strontium chloride Sr-89 ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing articles: Radiopharmaceutical Safety: Making It Easy Targeted Radionuclide Therapy: A Theranostic Approach to Cancer Therapy ONS Huddle Cards: Radiobiology Radiopharmaceuticals ONS Learning Libraries: Immuno-Oncology Radiation ONS Symptom Interventions for Prevention of Bleeding Drugs@FDA package inserts To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Radioimmunoconjugates are a specialized subset of radiopharmaceuticals designed to combine the specificity of monoclonal antibodies with the cytotoxic power of radiation. ... Early development focused on B-cell malignancies, particularly non-Hodgkin lymphoma." TS 1:51  "An important concept for nurses to understand is the crossfire effect, where radiation can affect nearby tumor cells, even though not every cell expressed has the target antigen. This helps explain why these agents can be effective even in heterogeneous tumors." TS 3:40 "At present, 90 Y-ibritumomab tiuxetan is the only radioimmunoconjugate approved by the U.S. Food and Drug Administration (FDA) in clinical use. Historically, iodine-131 tositumomab played a major role in establishing these therapy classes, but it's also useful to contrast radioimmunoconjugates with other radiopharmaceuticals, such as iodine-131 therapies, which a lot of places do at this time, used for thyroid diseases, or radium 223, used for metastatic prostate cancer. Unlike those agents, radioimmunoconjugates rely on antibody-mediated targeted rather than physiologic uptake or bone affinity." TS 4:55 "I just try to explain to [patients] that radiation exposure is like being next to a flame. The further you are away, the less heat you get, the less exposure you get. These patients can be radioactive for three days, seven days—it just depends on how fast they excrete it through their bodies with half-life exposure." TS 9:33 "While only one agent is currently approved, the principles established by radioimmunoconjugates continue to guide development for newer targeted radiopharmaceuticals. Emerging agents aim to improve targeting, reduce toxicity, and expand indications beyond hematologic malignancies. This evolution underscores the importance of nursing education in this rapidly changing field." TS 10:41 "Radioimmunoconjugates represent an important bridge between traditional oncology treatments and the future of targeted therapies. Oncology nurses play a vital role in ensuring safe delivery, patient understanding, and collaboration between multidisciplinary teams. So, it's very important to educate and also stay up to date on evidence-based practices." TS 13:12

Host Evie Stokes talks to KEXP DJ Reeves about his love of metal music and Speedclaw’s new song “Allnighter,” from their 2025 debut studio album Stardust via Dying Victims Productions. Produced by Lilly Ana FowlerMastered by: William MyersProduction support: Serafima HealyAssociate Director of Editorial: Dusty Henry Listen to the full songs on KEXP's "In Our Headphones" playlist on Spotify or the “What's In Our Headphones” playlist on YouTube. Support the podcast: kexp.org/headphonesContact us at headphones@kexp.org.Support the show: https://www.kexp.org/donateSee omnystudio.com/listener for privacy information.

Winter is here in the UK, so while Saul and Lucy hunker down, don layers and fire up the kettle more frequently than usual, what do their minds turn to in the garden? This is the perfect season for clearance of 2025 growth, for establishing new designs and for de-cluttering stores and greenhouses. Any hours that you can put into the garden now, will reward you hugely come spring and summer, when the jobs mount up. Quick - more tea and biscuits!With Saul having indoor mouse problems (three of them!) and Lucy admitting her addiction to homogenous gravel, the duo reveal what really presses a professional gardener's buttons during winter. Thankfully, rose pruning season is also in earnest so Lucy is getting her horticultural fix. Saul has been pressing new buttons, too (see his instagram link, below) and discovering that in social media world, January is the new February for seed sowing. Is this wise, or should seed packets remain closed a little longer? Listen in to find out their thoughts...Instagram link:Saul plantsmansaulLucy lucychamberlaingardensLinkedIn link:Saul WalkerIntro and Outro music from https://filmmusic.io"Fireflies and Stardust" by Kevin MacLeod (https://incompetech.com)License: CC BY (http://creativecommons.org/licenses/by/4.0/)Support the show

In this episode, we're diving into Danny Brown's latest album, Star Dust. Our host shares their honest thoughts on the project, highlighting both the growth and the challenges they faced while listening. From the opening track "Book of Daniel" to the experimental sounds of "Flowers," they discuss how Danny Brown's evolution as an artist is both impressive and sometimes polarizing. We're also joined by Ken, who shares his own take on the album, weighing in on the production, lyrics, and features. It's a conversation that's all about embracing Danny Brown's unique style and the impact it's having on the hip-hop landscape.See omnystudio.com/listener for privacy information.

"The United States does not have a national cancer registry. We have a bunch of state registries. Some of those registries do collaborate and share information, but the issue is the registries that do exist typically do not report cancer by occupation. So, we cannot get our arms around the potential work-relatedness of the health outcome given the current way the state registries collect information. What we're trying to set up, is a way to make what is currently an invisible risk, visible," ONS member Melissa McDiarmid, MD, MPH, DABT, professor of medicine and epidemiology and public health director of the division of occupational and environmental medicine at the University of Maryland School of Medicine in Baltimore, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the University of Maryland School of Medicine Hazardous Drug Safety Center Exposure Registry. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 23, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the incidence of hazardous drug exposure and the tracking and reporting of healthcare worker exposures. Episode Notes  Complete this evaluation for free NCPD. University of Maryland School of Medicine Hazardous Drug Safety Center Exposure Registry information sheet ONS Podcast™ episodes: Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 308: Hazardous Drugs and Hazardous Waste: Personal, Patient, and Environmental Safety Episode 209: Updates in Chemo PPE and Safe Handling ONS Voice articles: Hazardous Drug Surface Contamination Prevails, Despite More Diligent PPE National Hazardous Drug Exposure Registry Safeguards Oncology Professionals NIOSH Releases Its 2024 List of Hazardous Drugs Safe Handling—We've Come a Long Way, Baby! Strategies to Promote Safe Medication Administration Practices Surfaces in Patient Bathrooms Often Contaminated With HDs, Despite Use of Plastic-Backed Pads ONS books: Safe Handling of Hazardous Drugs (fourth edition) Safe Handling of Hazardous Drugs Quick Guide™ ONS course: Safe Handling Basics Clinical Journal of Oncology Nursing articles: Hazardous Drug Exposure: Case Report Analysis From a Prospective, Multisite Study of Oncology Nurses' Exposure in Ambulatory Settings Personal Protective Equipment Use and Surface Contamination With Antineoplastic Drugs: The Impact of the COVID-19 Pandemic Sequential Wipe Testing for Hazardous Drugs: A Quality Improvement Project The Use of Plastic-Backed Pads to Reduce Hazardous Drug Contamination Oncology Nursing Forum articles: Ensuring Healthcare Worker Safety When Handling Hazardous Drugs Factors Influencing Nurses' Use of Hazardous Drug Safe Handling Precautions Other ONS resources: ONS Safe Handling of Hazardous Drugs Quick Guide Introduction to Safe Handling Huddle Card Safe Handling of Hazardous Drugs Learning Library Hematology/Oncology Pharmacy Association (HOPA) course: Safe Handling of Hazardous Drugs National Institute for Occupational Safety and Health (NIOSH) List of Hazardous Drugs in Healthcare Settings, 2024 To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We thought that in order to answer some of the unclear questions about health risk, we would set up an exposure registry, in this case, for oncology personnel who handle the drugs. This would then create a cohort that we could ask questions to. For example, we could try to characterize whether there is a cancer excess in this group. Or characterize the reproductive abnormalities in excess that people are experiencing." TS 6:21 "It's sort of counterintuitive that the healthcare industry, whose mission itself is care of the sick, is a high-hazard industry. We typically think about the risk as being from infectious diseases, and certainly we've all lived in our practice lifetime through some examples of that. Even before COVID-19, some of us were doing preparation for Ebola and that sort of thing. So, we're kind of used to that. But the hazards that you kind of grew up with, we've routinized or normalized handling group one, human carcinogens, which a number of these drugs are—it's just something we do every day. Well, it is, but we have to do it with respect and with care every day. And I think sometimes in that routineness of it, we have sort of lost sight of the vigilance that we need to maintain." TS 11:19 "It's very easy in the life cycle of a drug in an organization to do something that doesn't just impact you, but unknowingly, you've contaminated a surface for somebody who comes behind you. Who maybe doesn't have plastic protective equipment on because something that got contaminated shouldn't have been contaminated in the first place. If we could all be thinking of it as more of a team sport, especially in terms of safe handling, that our disposition and drug handling affects not just us and our health, but those of our colleagues." TS 24:47 "For the job history pieces, we ask what year you started, what year you stopped, and we ask about estimations of handling. So we'll be able to come up with either a duration or some kind of metric for the intensity and duration of your handling history, which will then permit us to sort the population who completed the survey into sort of low, medium, high. And we'll see whether the health outcomes that are being reported are influenced by that drug handling history." TS 27:45 "The idea that we aren't exposed to the same therapeutic dose we give to our patients is absolutely true. However, the dosing schedule to them versus us is very different, and we are exposed frequently, if not daily, to very small concentrations. They don't reach a cytotoxic dose necessarily, but we do know from a lot of studies that either ourselves or our colleagues are taking up drug from contaminated work environments. And you've probably seen there is an awful lot of intermediate evidence looking at genotoxic insult in pharmacists and nurses who handle the drugs. So clearly we're showing uptake and we're showing that there are biologically plausible, concerning measures that are taking place in us. So, I think that we need to come back and circle around the idea that we need to have deep respect for the toxicity of these agents." TS 35:03

Stardust Bones 2025 - Teaching Painting from one of the last Intentional Creativity Certifications, this is the painting that sparked the change. This is my story in a single image with hundreds of stories within…Dear Ones, Today I'm reminded of a letter that I received in 2020 from our Elder Carmen Baraka. It was written to me and Jonathan, and here's one quote that I love. “To know you are between worlds, the I am that I am. I am most comfortable here in this place of giving and receiving. In this place of quantum identity where you find out and can feel this realm in a profound way. An actual view that we are all interconnected in alignment with the stars. When you can actually experience what you feel is your deepest truth. Hold it in your hand and have it be tangible. That is the gift. That is pure joy. That is the awakening.” Carmen Baraka. For those of you that don't know, Carmen was our indigenous elder within all of our communities. We got to guide ceremony together for over 10 years. She walked into her future in 2021 right before my mom, Caron McCloud So today, I'm signaling a change (breathing)And I want to begin with acknowledging that everyone in our community of Musea is a part of my life. MUSEA means many museums and many muses in the plural. MUSEA goes on. The Intentional Creativity Foundation, our 501c3, will continue with Musea. MUSEA is the greater community, a collective.My art studio, is just one MUSEA, albeit it's an important one. Yet I am taking my position as another artist in the lineage of Intentional Creativity Teachings, and I remain the Co-founder with Jonathan McCloud. Yet, it is essential for me at this time to curate my personal part of our work. Since 2008, the first legend, I've been bringing forth the lineage teachings as they came through. Nine certifications later, I am complete with that particular transmission with the last Legend and the last Color of Woman that I will personally lead. And all of that completes in March 2026 with our All Tribes Gathering, which is for Graduates and Guild members of the certifications.Legend was a significant course for me. Because before 2008, I had already created a million dollars worth of revenue with my paintings. I had galleries in San Francisco and Sausalito, Sonoma and Mendocino. I was living the life of a fine artist and having pretty incredible success, all things considered. But then it occurred to me….And I remember because I was with Mary MacDonald, it occurred to me that maybe what people wanted instead of my paintings, well not instead, but like more than my paintings, is to be able to paint their own. They were drawn to my images so powerfully, it was more than just about a painting.We took the huge leap and we decided to teach the first legend. Mary, my mother Caron, and my other mother Sue sat down at the table that's right in this room with me, that I call the Feast Table of Love. We sat down and we reverse engineered a way to make a painting. ALSO let it be known that it was Mary MacDonald that said - “Let's turn on the camera and see what she does”The rest is herstory.Because even though I had the opportunity to be trained in painting, we say Painting with a capital P, which is a more fine art way of painting, I did not take well to it. And Sue had to create what she called “a way of working” which is not, in her world, painting with a capital P.It's like making a way through for someone who really isn't able to follow the how to paint instructions. And so Legend was literally the reverse engineering of the 13 steps of how to make a painting, if you don't know how to paint, that Sue designed for me. And we labeled them and named them. And now we've taught it. literally to thousands and thousands and thousands of people and probably over 800 graduates who learned the 13 steps. And it literally still works to this day… and when I'm teaching paintings of the feminine form, I still use almost the exact formula because it's basically a build.My husband at the time, Isaiah, was so concerned that if I taught people my method, we would lose all of our money. And guess what? I thought we wouldn't. And guess what? We did. There was a moment at the completion of that marriage, actually, when we went to zero after creating so much abundance for ourselves and investing so heavily in community.It turns out Intentional Creativity and the feminine image is what women wanted. They wanted to paint their own image more than they wanted to purchase my paintings. I still sell paintings, by the way. I have lots available lol. But now thousands and thousands of people have their own images instead of mine. What an incredible journey. So it took a while to rebuild with this model. But at that moment, something happened… I moved out of the individual serving my own creative desire and I moved into this bigger framework of serving the community with the feminine image. There's so much behind why that matters, and why that's important and how we've had 40,000 years of images of the feminine and then the past 5,000 to 8,000 years intentional silencing and erasing of the feminine and her presence. When women reclaim the feminine image it is so huge, and to do that instead of my own paintings has been so powerful!!And it's also emotional because my style changed dramatically to reverse engineer it for others. I look at my paintings before I started teaching and I wonder where I'd be.. how I might have developed… a but I really did put my work in service to creation. I really did do the great work of the Ancestors. I really did bring through what my mothers taught me, and with the help of Mary MacDonald and Jennifer Owen and Elizabeth Gibbons in particular, brought forward Intentional Creativity at an all gorgeous level. I then taught it since 2008 until this year. I didn't expect to get so emotional. Tears flowing. So it is essential for me at this time to begin my own work with painting and writing. And it will still be in service to the community, but in a different way because it won't be certifications which require such a high level of integrity and management. The certifications will continue to be managed by the Intentional Creativity Foundation, our 501 c3. My own work begins nowand of course it's still connected with all of you. It's called the Stardust Lineage. It's the evolution of Cosmic Cowgirls, whose anniversary founding is today in 2004. I have no idea what my new work is going to be yet, and I suspect that the new work is the old work in different forms. Especially this year because I'm crossing a bridge of change and going one step at a time across that bridge. I'm not running across. I still have lots of work to do to complete, and it's utterly overwhelming to complete a legacy while you're alive. (More tears)Of course, whatever I do will be connected with MUSEA. Of course, whatever I do is coming from the Ancestors, and it's also my work now. Of course, Intentional Creativity will continue. That is my work and many of our work. But it's time for me, having delivered what feels like the great work of the ancestors, to now begin to reveal my own. The work started when they were living, but continues after. And so many of the teachings, they came through my “shiloh filter” but they weren't really from me. I could never just bring that out. I think of Carl Jung's Red Book where he said that there was more than enough material for one lifetime and that it was so much that it threatened to break him.In 1957, near the end of his life, Jung spoke about the Red Book and the process which yielded it; in that interview he stated:“The years… when I pursued the inner images, were the most important time of my life. Everything else is to be derived from this. It began at that time, and the later details hardly matter anymore. My entire life consisted in elaborating what had burst forth from the unconscious and flooded me like an enigmatic stream and threatened to break me. That was the stuff and material for more than only one life. Everything later was merely the outer classification, scientific elaboration, and the integration into life. But the numinous beginning, which contained everything, was then.”For me, there were moments when there was so much coming through, I was like how am I gonna get this all down in time??!!?? And I did it. And I did it with all of you who participated in the certification. I don't know what my work is going to mean from now on. I know that I had to do Path of Mystics, guiding women to develop their intuition and their spiritual gifts as a part of it. I have a teaching for healers and entrepreneurship. That's a part of it. I mean, I'm going to keep teaching because that's what I am. I'm just not going to do the certification. I'm also changing the name of the Sonoma property from MUSEA Center to Stardust Ranch. That's a part of it. Stardust Ranch is a MUSEA Center. It's just that holding and financing the entire container for the community isn't something I can physically and financially do anymore. I have to make it more personal to me and my work because most of the time, I'm there by myself. it's a huge space to be in, 6,500 square feet and it's a community space but the community is not there like except for events and that's like one or two times a month. So I have to make it my own somehow in order to continue. But we're still a MUSEA Center. All right, let me get through this. The truth is that my brain has been entirely occupied with the certifications and the structure of the community, aka the corporation, the legality, the paperwork. Oh my gosh, I have like four corporations. It's just insane. I want something much more simple for myself. And I haven't had the spaciousness to develop my own work. I really haven't. I haven't developed my own painting.There just wasn't enough hours and brains in the day. This work had to come through and I let it because this work was the work of this lifetime. It's work for these times. Intentional Creativity is what to do in times of chaos and suffering. It just is. It works. It helps every time.I believe in Intentional Creativity so powerfully… and I I don't regret it, although I have my moments. As most of you know, I didn't get to have children. I wanted to. And many miscarriages. And I think of that one child who kept trying to come through as an ancestor now, Her name is Musette. She's mine and Jonathan's love child. And the mother love that I had for that child, literally since the time I was born, I knew she was coming. That love went into this work. I gave the mother love I had into the community and this matriarchal space that we co-create.So I want you to know I'm not stepping out. I'm stepping in. But as the artist and as the author. Here I go. Oh, so slowly. Slowly. The reveal is almost suspenseful as my Soul is offering only one little glimmer at a time. And this is all I can take, really.Because I still have months and months of work and paperwork and emails to edit and pages to build to complete this cycle in a good way. As you likely know, some of you don't. My beautiful husband, Jonathan, and I, we completed our marriage at the end of last year, 12-31-2025. Our deep abiding friendship and connection is growing daily. And we've spent lots of time together over the past couple weeks. Including today, we're going to be together. We are teaching a new Apothecary based on his work called Chaos is the New Black. And the class is Apothecary, which was always his curriculum. But this one is going to be even more so rooted in his work. And I'm the backup singer on this one. On 12-12, the feast day of Our Lady, with the support of my CFO (Jen) and my best friend Amy Ahlers and Jonathan and Michelle Pappe and Ali Stoddard and many community members on so many levels, I moved to Sonoma Mountain. Sonoma Mountain is the birthplace of creation of the Coastal Miwok people and is in the glen called Glen Ellen. This is actually one of the places of my first significant trauma of being removed from my home because we were under threat because my family was protecting women. Interestingly enough, I had a space clearing person clear the ranch in another part of Sonoma County, like 20 minutes from here. And they said I was forcibly removed from that property in another lifetime. So I have this pattern of being removed against my will. And then the fires just perpetuated that.So I find it interesting that I'm back on the mountain to complete my life here. I pray I never have to move. And if I do, then I accept that. But I'm moving in as if I'm going to stay forever. There's a burnt ridge out my bedroom window and it reminds me that everything is temporary and I honor that…and so unless fire or flood make me move I'm hoping to stay here. I am grateful to have purchased a home with the generosity of the Ancestors who made it possible. Because I did not personally have enough to make it happen. But my Ancestors made an offering that's old, old, from my grandparents on my father's side. And I was able to purchase this home with the down payment. Humbled, grateful, in awe.Meanwhile, the world around us needs Intentional Creativity more than ever. And even with that need of the world, I need to find a way to myself, my original Legendary self.My first legend painting is coming true now. This is that place, and Stardust Ranch, is that ranch where my Legendary self works. So I will be in circle with all of you for the next 500 years. So please do not think I've gone anywhere. The Cura Council is the place where all the communities converge in ceremony.I'm not going anywhere. Quite the opposite. I am right here. with my quantum identity, emerging my Legendary Self. Stardust Lineage is the name for my personal work, but held within the greater framework of the Intentional Creativity Teaching. So you could just think of it as my MUSEA Center, called Stardust Ranch.My teachings are through the Stardust lineage. And anyone who works with me becomes a part of that. So this is a life…a story…a lineage to be continued. Big, big love. I just want to say that the biggest love I've ever experienced, what Carmen calls quantum love, which was the name of the subject line of that email, Quantum Love…Learning to love people that I've never met, learning to love you so much that I would actually stop my own art career and painting process in order to see if that's what you wanted. Loving you so much to give the mother love I had for my own baby to all of you. To Love you in that quantum way, meaning virtual, to reach people across the miles. I'll never forget the feeling on that first day that we Live streamed. He brought the technology. and I was able to reach you all. Not just through video. But through live transmission. Everything changed. That was in 2013. And amazingly. About nine months ago, I was brought in to be a speaker at a place called Edge City that was in Healdsburg, a pop-up. Literally my exact teaching spot to broadcast from was that exact building where Cosmic Cowgirls was and the exact spot where I first taught the very first live stream. You can't make this stuff up. You know what I mean? You just can't make it up. I have so many more things to say, but I'll keep saying them.That quantum love is the biggest experience that I've ever had in my lifetime, and I try to teach it to all of you. I think it's the key, actually, to our intuitive gifts and spiritual transmissions and businesses and even income and being able to create what you love with joy and service is this feeling of loving someone that you've never met. The first time I ever heard about it was reading in a book from Pema Chodron where she talked about the Bodhisattva, which is this unreasonable desire to end suffering. And in particular for people that you've never met. I'm not saying I'm a Bodhisattva or anything, but that feeling of loving you. It's huge. It's my biggest experience. It is quantum love and I can't recommend it enough. And I think I do see it all the time, because you fall in love with each other. And friendships happen when you've never even met. Sometimes at the Stardust Ranch, I get to see you meeting each other for the first time. And sometimes people come, like a new and special friend, my Star, who come and they say, I'm here for this. I'm part of this lineage. So my life continues in this curious and delightful way. Love is here. Relationship is here. Evolution is here. Sharing my new household with someone that I love is here. Healing is here. The ongoing story of the Stardust Lineage is right here as the sun comes up over the mountain and shines its light in my home. Breathing through this share, thank you for caring enough to listen and loving me in the quantum way that you do. Sue had a painting that said, I have loved you from my deepist heart. So dear ones, with the deepist heart love and stardust, I love you. I'm grateful for you. May our journey continue for generations to come. I'll be here.Will you?p.s. on the painting she spelled it, deepist. Get full access to Tea with the Muse at teawiththemuse.substack.com/subscribe

Winter is here in the UK, so while Saul and Lucy hunker down, don layers and fire up the kettle more frequently than usual, what do their minds turn to in the garden? This is the perfect season for clearance of 2025 growth, for establishing new designs and for de-cluttering stores and greenhouses. Any hours that you can put into the garden now, will reward you hugely come spring and summer, when the jobs mount up. Quick - more tea and biscuits!Finally the #hortiwaffle returns, as Saul has managed to break the surface of his new job and the information overload that is coming his way, and spend some time digesting his first few exciting weeks with Plant Heritage. Lucy, fresh of a false start week, is back into compost turning and topiary pruning. But the pair are really enjoying the winter structure the garden provides at this time of year, the promise of new growth to come and most of all enjoying another year in the wonderful world of horticulture!Instagram link:Lucy lucychamberlaingardensSaul plantsmansaulLinkedIn link:Saul WalkerIntro and Outro music from https://filmmusic.io"Fireflies and Stardust" by Kevin MacLeod (https://incompetech.com)License: CC BY (http://creativecommons.org/licenses/by/4.0/)Support the show

"[Multiple myeloma] is very treatable, very manageable, but right now it is still considered an incurable disease. So, patients are on this journey with myeloma for the long term. It's very important for us to realize that during their journey, we will see them repeatedly. They are going to be part of our work family. They will be with us for a while. I think it's our job to be their advocate. To be really focused on not just the disease, but periodically assessing that financial burden and psychosocial aspect," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about multiple myeloma. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 16, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the pathophysiology and diagnosis of multiple myeloma. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 332: Best Nursing Practices for Pain Management in Patients With Cancer Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 192: Oncologic Emergencies 101: Hypercalcemia of Malignancy ONS Voice articles: AI Multiple Myeloma Model Predicts Individual Risk, Outcomes, and Genomic Implications Cancer Mortality Declines Among Black Patients but Remains Disproportionately High Financial Navigation During Hematologic Cancer Saves Patients and Caregivers $2,500 Multiple Myeloma: Detecting Genetic Changes Through Bone Marrow Biopsy and the Influence on Care Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations Nurse-Led Bone Marrow Biopsy Clinics Truncate Time for Testing, Treatment Diagnose and Treat Hypercalcemia of Malignancy ONS books: BMTCN® Certification Review Manual (second edition) Multiple Myeloma: A Textbook for Nurses (third edition) Clinical Journal of Oncology Nursing articles: African American Patients With Multiple Myeloma: Optimizing Care to Decrease Racial Disparities Music Intervention: Nonpharmacologic Method to Reduce Pain and Anxiety in Adult Patients Undergoing Bone Marrow Procedures Other ONS resources: Financial Toxicity Huddle Card Hypercalcemia of Malignancy Huddle Card Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Cancer Society article: What Is Multiple Myeloma? Blood Cancer United educational resources page International Myeloma Foundation homepage Myeloma University homepage Multiple Myeloma Research Foundation (MMRF) article: Understanding Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Epidemiologically, myeloma is a cancer of older adults. The median age is about 69. It is more common in men than women. It's a ratio of about three men to two women that are diagnosed. It is much more common in people of African American descent with increasing global incidence linked to aging populations. Although, the highest rates are in high-income countries. So, if we look at some of the risk factors, and several have been identified, including MGUS. MGUS is a benign precursor of myeloma, and it stands for monoclonal gammopathy of undetermined significance. Older age is also a risk factor, although we do see patients that are younger who are diagnosed with myeloma." TS 1:54 "Bone pain, specifically in the back, and fatigue, are very common symptoms that relate to things that are going on behind the scenes with myeloma. But also, patients can be bothered by frequent and long-lasting infections. So, they find that they get sick more frequently than their family and friends, and they take a longer time to recover. That could also be a presenting sign. I think there can be some presenting signs and symptoms related to electrolyte abnormalities, especially in later stages. They might be nauseated, vomiting, or constipated. Also, signs and symptoms related to cytopenias. You have to remember that this is a bone marrow cancer. So, we do have some problem with development of normal blood cells. So, we can see not only infections, but bleeding issues related to thrombocytopenia and factors related to anemia from low red blood cell counts." TS 7:15 "About 20%–25% of our patients who are diagnosed are asymptomatic. They have no symptoms. They're living their lives, they're going to work or they're traveling, playing golf on the weekends, taking care of their children or grandchildren. They are just living their lives. And at times, they go to the primary care physician and then they're referred to a hematologist-oncologist, and they're pretty surprised when they're sent to a cancer center. The way they are diagnosed in this matter is that their routine lab work, the complete blood cell count may be normal, there may be some slight differences in their hemoglobin. But what we see in the chemistry, the complete metabolic panel, is an elevation in their total protein and or an elevation of the total globulins." TS 9:22 "The bone marrow biopsy serves many purposes. You want to determine the percentage of bone marrow plasma cells. So, you want to get the degree of plasmacytosis. And then you want to do really specific tests on those plasma cells. So, you want to isolate the malignant plasma cells and determine, via analysis. So, we do the karyotype, chromosomal studies, fluorescence in situ hybridization (FISH) studies, immunohistochemistry studies, and molecular studies. All of these studies are looking for specific genetic changes in the myeloma cells—looking for translocations or deletions. And it's very important to get that information because we can put patients in a category of having standard-risk disease versus high-risk disease. And that can give us a better picture of what this patient's journey with myeloma may look like." TS 13:41 "When I used to work in lymphoma, I spoke with the physicians who were lymphoma specialists, and they said that they foresee a future in having these assays that detect circulating tumor cells actually take the place of imaging studies like restaging positron-emission tomography (PET), computed tomography (CT) scans. So, it's really amazing, these tests that are on the market now and maybe not as widespread as we'd like, but there's a lot of nice assays out there that will become more popular and used more commonplace in the future that I think are going to help identify myeloma more precisely. ... If you think about myeloma, even with measurable residual disease (MRD), MRD for leukemia, for lymphoma, you take a blood sample, you test it for MRD. For myeloma, you need a bone marrow biopsy. You need a bone marrow sample. You can't do MRD on a blood sample for myeloma. Not yet. But if we perfect these assays and we can eventually detect this, then you're looking at a whole new ballgame. You can even perfect your MRD testing as well. So, it's a very exciting time for some of these heme malignancies." TS 28:09

In this Thursday episode of Book Talk for BookTok, we bring an academic lens to bookish culture, genre fiction, and the conversations shaping romance and romantasy today. Our podcast blends literary analysis, cultural criticism, and emotional honesty. We treat romance, romantasy, and fanfiction as genres worthy of serious discussion, not just quick takes. This episode is part of our Subtext Society series, inspired by The Subtext Society Journal. The Subtext Society Journal is a collaborative publication dedicated to thoughtful essays on romance, romantasy, fan culture, and publishing ethics. We explore moral questions, genre evolution, power dynamics, and the real-world impact of stories, guided by values of literary rigor without gatekeeping, community over hierarchy, and ethics-first analysis. Today's discussion focuses on the article: “Is Dark Romance Allowing a Dark Space?” Using the Sinners and Stardust controversy as a case study, we examine accountability in fandom spaces, consent versus cosplay, and whether increased freedom within romance and dark romance has been misunderstood or misused. This conversation challenges us to hold women to the same ethical standards as men, interrogate harmful behavior without demonizing the genre itself, and ask how communities can protect spaces meant to feel safe. Trigger Warning: This episode includes discussion of sexual assault, sexual harassment, and non-consensual behavior. Listener discretion is advised. These Subtext Society episodes are designed to be reflective, critical, and grounded— creating space for nuance, responsibility, and care within the bookish community. How to participate: Send your theories and spicy takes by commenting on this episode, DMing us, or using the form on our website. The Subtext Society Journal: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://thesubtextsocietyjournal.substack.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  We're thrilled to announce our newest venture: The Subtext Society Journal—the first of its kind, dedicated to Romance, Romantasy, and fandom with an academic yet accessible voice. We're publishing original essays and thought pieces, and we encourage listeners to submit their own articles for a chance to be featured. Sponsor: Vionic Use code BOOKTALK at checkout for 15% off your entire order at www.vionicshoes.com when you log into your account. 1 time use only. Share your thoughts for a chance to be featured! Submit them at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠booktalkforbooktok.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ for a future mini-episode or exclusive Patreon discussion. Support the Show:  Patreon: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/booktalkforbooktok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Merch: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Etsy Store⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow Us on Social: Instagram: @BookTalkForBookTok TikTok: @BookTalkForBookTok YouTube: @BookTalkForBookTok Learn more about your ad choices. Visit megaphone.fm/adchoices

This week, we're closing out Capricorn season in style, grounding the practical magic with a powerful New Moon before the cosmic winds shift and Aquarius season arrives next week. Mercury faces off with big-picture Jupiter, igniting bold conversations, visionary ideas, and a fresh wave of optimism. Meanwhile, Venus dances in harmony with Uranus and Neptune, weaving enchantment, inspiration, and a touch of cosmic sparkle before she makes her revolutionary move into Aquarius. Expect insight, imagination, and a hint of stardust—all this and more on The Golden Astrologer Podcast. ✨

durée : 00:56:52 - Very Good Trip - par : Michka Assayas - Et voilà, ça y est, le moment magique est presque arrivé. David Bowie est sur le point d'incarner le personnage de Ziggy Stardust, la première superstar fictive de l'histoire du rock. Un personnage désaxé, décadent, auquel Bowie restera éternellement associé et qui fera de lui une superstar. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Winter is here in the UK, so while Saul and Lucy hunker down, don layers and fire up the kettle more frequently than usual, what do their minds turn to in the garden? This is the perfect season for clearance of 2025 growth, for establishing new designs and for de-cluttering stores and greenhouses. Any hours that you can put into the garden now, will reward you hugely come spring and summer, when the jobs mount up. Quick - more tea and biscuits!And they're off! While Saul enjoys his new life in a warm, dry office, Lucy is dodging the weather whilst still attempting to earn a crust (thank goodness for gardening radio and magazines :-). Snowfall and storm Goretti force her to dance the merry winter waltz, as she sidesteps sleet and soggy spells. Her body also reminds her that two weeks of doing very little physically, followed by intense compost hurling then a rapid cooldown, spells a date with Mr Nurophen and Master Wheatbag. Onwards and upwards then, for next week!LinkedIn link:Saul WalkerInstagram link:Lucy lucychamberlaingardensIntro and Outro music from https://filmmusic.io"Fireflies and Stardust" by Kevin MacLeod (https://incompetech.com)License: CC BY (http://creativecommons.org/licenses/by/4.0/)Support the show

"Referring patients to audiology early on has shown dramatic reduction in hearing loss or complications because the audiologist can really see where were they at before they started chemotherapy, where were they at during, if they get an audiogram during their treatment. And then after treatment, it's really important for them to see an audiologist because this is really a survivorship journey for them. And as nurses, the 'so what': We are the first line of defense," ONS member Jennessa Rooker, PhD, RN, OCN®, director of nursing excellence at the Tampa General Hospital Cancer Institute in Florida, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ototoxicity in cancer care. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 9, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the management of ototoxicity after chemotherapy treatment. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ Cancer Symptom Management Basics series ONS Voice articles: Oncology Drug Reference Sheet: Cisplatin Oncology Drug Reference Sheet: Carboplatin Oncology Drug Reference Sheet: Oxaliplatin FDA Approves Sodium Thiosulfate for Cisplatin-Associated Ototoxicity in Pediatric Patients ONS book: Clinical Manual for the Oncology Advanced Practice Nurse (fourth edition) American Cancer Society resources: 4 Causes of Hearing Problems for Cancer Survivors Cancer Survivors Network American Speech-Language-Hearing Association (ASHA) Hearing Loss: An Under-Recognized Side Effect of Cancer Treatment Embedded Ear Care: Audiology on the Cancer Treatment Team American Society of Clinical Oncology (ASCO) Annual Meeting abstract: Innovative Infusion Center Assessments of Chemotherapy-Induced Neurotoxicities: A Pilot Study Supporting Early and Routine Screenings as Part of Survivorship Programs Children's Oncology Group supportive care endorsed guideline: Prevention of Cisplatin-Induced Ototoxicity in Children and Adolescents With Cancer: A Clinical Practice Guideline Ear and Hearing article: Roadmap to a Global Template for Implementation of Ototoxicity Management for Cancer Treatment International Ototoxicity Management Group (IOMG) IOMG Wikiversity page Shoebox hearing assessments World Health Organization initiative: Make Listening Safe To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "At different pitches, the eardrums move faster or slower, signaling the inner ear, or the cochlea—the thing that looks like a snail in the pictures. The cochlea has fluid and hair cells inside of it that receive movements from the eardrum. The hair cells change the movement into electrical signals that actually go to the auditory nerves or the cranial nerve VIII." TS 2:15 "Ototoxicity is an umbrella term for some sort of exposure to a toxin that causes damage to the inner ear. These toxins can be in the environment, such as loud or different noises, or they can be from medications, including antibiotics or commonly cancer treatments, such as radiation chemotherapy. Some common chemotherapies can be platinum-based chemotherapies like cisplatin or carboplatin. And then what patients are experiencing if they have ototoxicity can be hearing loss." TS 3:15 "The hypothesized mechanism of action is that the chemicals like the platinum compound in cisplatin … that platinum compound travels through our bloodstream. Since chemotherapy is systemic, it'll go to the inner ear, and it gets stuck there by binding to the cellular DNA in that cochlea, or that snail-looking image. That initiates the release of the reactive oxygen species, which are really trying to help clean it out, but releases such high levels that it ends up causing damage to those inner ear hairs. These inner ear hairs cannot regenerate themselves, so then they're permanently damaged. And remember we said that those hairs send electrical signals to the brain that recognize sound. So that function is permanently gone once those hair cells are damaged." TS 7:10 "I definitely think this is a huge interdisciplinary collaborative effort. As nurses and advanced providers, we're assessing and providing education. Our medical oncologists are doing those dose modifications and submitting those audiology referrals. The radiation oncologists are very important to know about this—maybe dose localization awareness. Maybe they do some changes with the doses. And then our audiologists and [ear, nose, and throat physicians], they can do that diagnostic confirmation and any rehabilitation measurements and really monitor them throughout their journey as well. And nurse navigators play a huge part in making sure those patients get those referrals, because a lot of the time the audiologists aren't in the cancer clinic, so they may have to go to another location or may need help coordinating with all their appointments that they have." TS 22:28 "We had a really innovative way of monitoring the hearing that a couple other studies have also tested. It's a remote point-of-care hearing screen. It was on [a tablet] with calibrated headphones. And then it's a paid-for subscription to an audiology testing platform. … Myself, along with a couple of other nurses, were trained how to use this testing device with the tablet and the headphones and the software program. And it was a quick down-and-dirty portable hearing assessment for patients. So anyone who was new to cisplatin, never gotten cisplatin treatment before, was enrolled into the study, and they received a hearing test every time that they came for chemo, and we gave it to them during their hydration." TS 28:59  

The crew pursues a bounty in a high speed chase...   You do NOT need to listen to Overture to enjoy Anthem! If you have the appetite to listen to both, we recommend starting with Anthem, then going back to listen to Overture!   Gain access to an exclusive campaign, Shroud Over Saltmarsh, over on Patreon: https://legendsofavantris.com/patreon The Crooked Moon, a folk horror supplement for 5e, is available for preorder! Get the Crooked Moon at: https://thecrookedmoon.com/ Watch more D&D adventures in the world of Avantris live on Twitch: https://www.twitch.tv/legendsofavantris Check out our merch store: https://shop.legendsofavantris.com  Join our community on Discord: https://legendsofavantris.com/discord Watch our many campaigns on YouTube: https://legendsofavantris.com/youtube  All other links: https://linktr.ee/legendsofavantris   Watch the full episode here: https://youtu.be/hX9cE_YFGoI?si=s09CS_YTVG5qtloq

"We proposed a concept to the American Society of Clinical Oncology (ASCO), recognizing that extravasation management requires significant interdisciplinary collaboration and rapid action. There can occasionally be uncertainty or lack of clear guidance when an extravasation event occurs, and our objective was to look at this evidence with the expert panel to create a resource to support oncology teams overall. We hope that the guideline can help mitigate harm and improve patient outcomes," Caroline Clark, MSN, APRN, AGCNS-BC, OCN®, EBP-C, director of guidelines and quality at ONS, told Chelsea Backler, MSN, APRN, AGCNS-BC, AOCNS®, VA-BC, oncology clinical specialist at ONS, during a conversation about the ONS/ASCO Guideline on the Management of Antineoplastic Extravasation. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 2, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the management of antineoplastic extravasation. Episode Notes  Complete this evaluation for free NCPD. ONS/ASCO Guideline on the Management of Antineoplastic Extravasation ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 335: Ultrasound-Guided IV Placement in the Oncology Setting Episode 145: Administer Taxane Chemotherapies With Confidence Episode 127: Reduce and Manage Extravasations When Administering Cancer Treatments ONS Voice articles: Access Devices and Central Lines: New Evidence and Innovations Are Changing Practice, but Individual Patient Needs Always Come First New Extravasation Guidelines Provide Recommendations for Protecting Patients and Standardizing Care Standardizing Venous Access Assessment and Validating Safe Chemo Administration Drastically Lowers Rates of Adverse Venous Events This Organization's Program Trains Non-Oncology Nurses to Deliver Antineoplastic Agents Safely ONS books: Access Device Guidelines: Recommendations for Nursing Practice and Education (fourth edition) Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) ONS courses: Complications of Vascular Access Devices (VAD) and IV Therapy ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS Oncology Treatment Modalities Clinical Journal of Oncology Nursing articles: Chemotherapy Extravasation: Incidence of and Factors Associated With Events in a Community Cancer Center Standardized Venous Access Assessment and Safe Chemotherapy Administration to Reduce Adverse Venous Events Oncology Nursing Forum article: Management of Extravasation of Antineoplastic Agents in Patients Undergoing Treatment for Cancer: A Systematic Review ONS huddle cards: Antineoplastic Administration Chemotherapy Immunotherapy Implanted Venous Port ONS position statements: Administration (Infusion and Injection) of Antineoplastic Therapies in the Home Education of the Nurse Who Administers and Cares for the Individual Receiving Antineoplastic Therapies ONS Guidelines™ for Extravasation Management ONS Oncologic Emergencies Learning Library ONS/ASCO Algorithm on the Management of Antineoplastic Extravasation of Vesicant or Irritant With Vesicant Properties in Adults American Society of Clinical Oncology (ASCO) Podcast: Management of Antineoplastic Extravasation: ONS-ASCO Guideline To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The focus of this guideline was specifically on intravenous antineoplastic extravasation or when a vesicant or an irritant with vesicant properties leaks out of the vascular space. This can cause an injury to the patient that's influenced by several factors including the specific drug that was involved in the extravasation, whether it was DNA binding, how much extravasated, the affected area, and individual patient characteristics." TS 1:48 "The panel identified and ranked outcomes that mattered most with extravasation. Not surprising, one of the first was tissue necrosis. Like, 'How are we going to prevent tissue necrosis and preserve tissue?' The next were pain, quality of life, delays in cancer treatment: How is an extravasation going to delay cancer treatment that's vital to the patient? Is an extravasation also going to result in hospitalization or additional surgical interventions that would be burdensome to the patient? ... We had a systematic review team that then went in and summarized the data, and the panel applied the grading of recommendations, assessment, development, and evaluation (GRADE) criteria, grading quality of evidence and weighing factors like patient preferences, cost, and feasibility of an intervention. From there, they developed their recommendations." TS 7:35 "The panel, from the onset, wanted to make sure we had something visual for our readers to reference. They combined evidence from the systematic review, other scholarly sources, and their real-world clinical experience to make this one-page supplementary algorithm. They wanted it to be comprehensive and easy to follow, and they included not only those acute management steps but also guidance on 'How do I document this and what are the objective and subjective assessment factors to look at? What am I going to tell the patient?' In practice, for use of that, I would compare it to your current processes and identify any gaps to inform policies in your individual organizations." TS 16:34 "The guidelines don't take place of clinician expertise; they're not intended to cover every situation, but a situation that keeps coming up that we should talk about as a limitation, is we're seeing these case reports of tissue injury with antibody–drug conjugate extravasation. There's still not enough evidence to inform care around the use of antidotes with those agents, so this still needs to be addressed on a case-by-case basis. We still need publication of those case studies, what was done, and outcomes to help inform direction." TS 19:24 "Beyond the acute management is to ensure thorough documentation regarding extravasation. Whether you're on electronic documentation or on paper, are the prompts there for the nurse to capture all of the factors that should be captured regarding that extravasation? The size, the measurement, the patient's complaints. Is there redness? Things like that. And then within the teams, everyone should know where to find that initial extravasation assessment so that later on, if they're in a different clinic, they have something to go by to see how the extravasation is healing or progressing. ... I think there's an importance here, too, to our novice oncology nurses and their preceptors. This could be anxiety-provoking for the whole team and the patient, so we want to increase confidence in management. So, I think using these resources for onboarding novice oncology nurses is important." TS 22:34

This week on the Primo show, Jesse and Katie discuss dark romance, Morning Glory Milking Farm, and a scandal at the 2025 dark rom con Sinners and Stardust. Plus, an FDB beef update. To hear more, visit www.blockedandreported.org

"They [monoclonal antibodies] are able to cause tumor cell death by binding to and blocking to necessary growth factor signaling pathways for tumor cell survival. That's going to be dependent on the target of the antibody, but I'll give an example of epidermal growth factor, or EGFR. This is overexpressed in several different kinds of cancers where activation of this growth factor increases the amount of proliferation and migration of cancer cells. So, if we bind to it and block to it, then that would help halt these pathways and stop cancer cell growth," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about monoclonal antibodies. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) (including 45 minutes of pharmacotherapeutic content) by listening to the full recording and completing an evaluation at courses.ons.org by December 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of monoclonal antibodies in the treatment of cancer.  Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 383: Pharmacology 101: Bispecific Antibodies Episode 375: Pharmacology 101: VEGF Inhibitors Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors ONS Voice articles: An Oncology Nursing Overview of Biosimilars Make Subcutaneous Administration More Comfortable for Your Patients Oncology Nurses' Role in Translating Biomarker Testing Results Reduce Chair Time by as Much as 16 Minutes by Priming IVs With Drug Shorter Administration Times Still Require High-Acuity Care The Names of Targeted Therapies Give Clues to How They Work ONS Voice drug reference sheets: Datopotamab deruxtecan-dlnk Enfortumab vedotin Margetuximab-cmkb Mirvetuximab soravtansine-gynx Nivolumab and hyaluronidase-nvhy Nivolumab and relatlimab-rmbw Pembrolizumab and berahyaluronidase alfa-pmph Retifanlimab-dlwr ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial Management of Immunotherapy Infusion Reactions Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oncology Nursing Forum articles: Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer Depressive Symptoms and Quality of Life Associated With the Use of Monoclonal Antibodies in Breast Cancer Treatment ONS huddle cards: Bispecifics Checkpoint Inhibitors Monoclonal Antibodies Other ONS resources: Biomarker Database Bispecific Antibodies video Patient Education Sheets Antibodies article: A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy Cureus article:  A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach Association of Cancer Care Centers (ACCC) homepage Cancer Immunology, Immunotherapy article: Therapeutic Antibodies in Oncology: An Immunopharmacological Overview Drugs@FDA package inserts Future Oncology article: Biosimilars: What the Oncologist Should Know Hematology/Oncology Pharmacy Association homepage National Comprehensive Cancer Network homepage Network for Collaborative Oncology Development and Advancement (NCODA) subcutaneous therapy article Oncolink: Side Effects of Immunotherapy World Health Organization: New International Nonproprietary Names (INN) Monoclonal Antibody Nomenclature Scheme To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Prior to monoclonal antibodies, all we really had were these toxic chemotherapies or toxic radiation, so it was recognized how great it would be if we could have a treatment that was much more specific to the tumor cells and have agents that have less toxicities. These advancements in monoclonal antibody production began in the 1980s. ... Eventually, we had the first monoclonal antibody that was approved by the U.S. Food and Drug Administration (FDA) for an oncologic indication, rituximab." TS 4:14  "Nowadays, we do have treatments that are also considered tumor-agnostic. This is when a patient has a certain biomarker, then that treatment can be given and FDA approval was given, regardless what type of tumor the patient has. We typically see these kinds of tumor-agnostic therapies more so in patients who have recurrent or advanced diseases in solid tumors. One monoclonal antibody example that comes to mind is dostarlimab. That's a checkpoint inhibitor that's approved for patients who are deficient in mismatch repair mechanism." TS 23:48 "Our immune system constantly has this surveillance system and it's able to recognize foreign pathogens, abnormal cells, and even precancerous cells. And they're able to eliminate them before they become cancerous. But on the flip side, one of the regulatory mechanisms that we have so our immune system doesn't attack itself is the presence of checkpoints. When these checkpoints bind to their ligands, this can then act as an off switch so that, again, our immune system is not going to attack itself. But then the tumor cells can take advantage of this and actually use this mechanism to evade the immune system. So, when we're giving a checkpoint inhibitor, now we're removing that off switch. As a consequence, common adverse effects can include things like immune mediated adverse events. These most commonly affect the skin, gastrointestinal tract, and liver. Essentially, this can cause any '-itis' you can think of." TS 26:36 "Looking at strategies to prevent infusion reactions, one example is the use of premedication. If premedication is recommended, this typically includes any combination of antipyretics, which is typically acetaminophen. Antihistamine, which is typically an H1 antagonist like diphenhydramine. Although, there could be cases where we want to substitute this agent because maybe the patient has been tolerating therapy okay, and they're having a lot of side effects. So, we might use a second-generation antihistamine in some cases. The premedication may be given with or without some kind of steroid, whether that's methylprednisolone, hydrocortisone, or dexamethasone." TS 29:53 "We tend to think of monoclonal antibody usage to be primary oncology, but that's not really the case. The first monoclonal antibodies that were developed were not for oncologic indications, they were for transplant indication for cardiac indication. So, they're really diversely utilized across all specialties and medicines. We have monoclonal antibodies for hyperlipidemia, for neurology, for rheumatology, so the uses are so very expansive across all specialties." TS 41:01

In this special Xmas episode, John is joined by Adam Buxton and producer Joe Mount to discuss how they wrote, recorded and produced the album Buckle Up. Adam Buxton is a podcaster, actor, comedian and musician, best known for his long-running, award-winning Adam Buxton Podcast. Since launching in 2015, he's become one of the UK's most popular podcasters, with guests ranging from Paul McCartney to Tom Hanks. He's also appeared in films including Hot Fuzz and Stardust, and published two acclaimed memoirs. With his popular jingles at the heart of segments on his podcast and mid-2000s radio show, Adam began work on his debut record Buckle Up in 2022, enlisting Metronomy's Joe Mount as producer. Sitting down at Strongroom Studios, Adam and Joe dig into the sounds and ideas behind Buckle Up, exploring how to balance comedy with more serious songwriting, and why stripping back production can help reveal something more authentic. Tracks discussed: Dancing in The Middle, My Feelings, Skip This Track, Tea Towel GEAR GIVEAWAY COMPETITION Join the Christmas Giveaway on the Tape Notes Patreon Page TAPE IT Thanks to our friends at Tape It for supporting the podcast. Visit tape.it/tapenotes or use the promo code TAPENOTES in the app to get 20% off. QUBE Get 20% off at Qube Studio: https://www.theqube.com/ MAKENOISE PRO AUDIO Get 20% off all Franklin Audio products at https://makenoiseproaudio.com/ MUSIVERSAL Skip the waitlist and get your discount HERE LISTEN to ‘Buckle Up' here: https://lynkify.in/album/buckle-up/RmIMrCSB  Decca Records LINKS TO EVERYTHING TAPE NOTES   linktr.ee/tapenotes  Intro Music - Sunshine Buddy, Laurel Collective - https://lynkify.in/song/sunshine-buddy/YT47TLFI  GEAR MENTIONS The God Particle Soniccouture Native Instruments Roland System 100 Yamaha NS-10 Speakers Yamaha QY-20 Yamaha QY-70 Yamaha QY-100 Fender Stratocaster Tupperware Logic Pro OUR GEAR https://linktr.ee/tapenotes_ourgear HELP SUPPORT THE SHOW If you'd like to help support the show you can join us on Patreon, where among many things you can access full length videos of most new episodes, ad-free episodes and detailed gear list breakdowns. KEEP UP TO DATE For behind the scenes photos and the latest updates, make sure to follow us on:  Patreon: Tape Notes YouTube: Tape Notes Podcast Instagram: @tapenotes  Discord: Tape Notes To let us know the artists you'd like to hear, slide into our DMs, send us an email or even a letter. We'd love to hear!  Visit our website to join our mailing list: www.tapenotes.co.uk

"My 9th mix for my DJ residency at Stardust Radio Ibiza. You can listen to @ibizastardustradio by downloading the mobile app through the Apple or Android store, and these radio shows are also available streaming on SoundCloud and MixCloud from @ibizastardustradio. #djellisdee #progressivehouse #deephouse #melodichouse #ibizastardustradio #djmix #djset #ibizadj"

342 Mission Stardust w/Mark HolmesSteven is joined by Mark Holmes to discuss 1967's Mission Stardust! We hope that you enjoy our discussion. We would also suggest watching the movie first, because we do disagree about certain things in the movie during our discussion.Please send feedback to DieCastMoviePodcast@gmail.com or leave us a message on our Facebook page.Thanks for listening!

Winter is arriving in the UK, so while Saul and Lucy hunker down, don layers and fire up the kettle more frequently than usual, what do their minds turn to in the garden? This is the perfect season for clearance of 2025 growth, for establishing new designs and for de-cluttering stores and greenhouses. Any hours that you can put into the garden now, will reward you hugely come spring and summer, when the jobs mount up. Quick - more tea and biscuits!Will it snow this Christmas? Will Saul ever manage to finally retrieve all his plants from Stonelands? Will Lucy push the John Deere to breaking point this time? Only listening to this final episode of 2025 will answer these burning questions, as we get the ever truly authentic recollections of the professional gardening life. More importantly, though - what do Lucy and Saul think of the predictions for 2026, set by the RHS (luckily, the year of the tomato and the year of the tropicals are both in there). It's unlikely that either podcaster will be piercing their water butt anytime soon, though...Instagram link:Lucy lucychamberlaingardensLinkedIn link:Saul WalkerIntro and Outro music from https://filmmusic.io"Fireflies and Stardust" by Kevin MacLeod (https://incompetech.com)License: CC BY (http://creativecommons.org/licenses/by/4.0/)Support the show

"The thought of recurrence is also a psychosocial issue for our patients. They're being monitored very closely for five years, so there's always that thought in the back of their head, 'What if the cancer comes back? What are the next steps? What am I going to do next?' It's really important that we have conversations with patients and their families about where they're at, what we're looking for, and reassure them that we'll be with them during this journey and help them through whatever next steps happen," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer survivorship considerations for nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by December 19, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to survivorship nursing considerations for people with prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 390: Prostate Cancer Treatment Considerations for Nurses Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 201: Which Survivorship Care Model Is Right for Your Patient? Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: APRNs Collaborate With PCPs on Shared Survivorship Care Models Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Here Are the Current Nutrition and Physical Activity Recommendations for Cancer Survivors Nursing Considerations for Prostate Cancer Survivorship Care Regular Physical Activity and Healthy Diet Lower Risk of All-Cause and Cardiac Mortality in Prostate Cancer Survivors Sexual Considerations for Patients With Cancer Sleep Disturbance Is Part of a Behavioral Symptom Cluster in Prostate Cancer Survivors ONS course: Essentials in Survivorship Care for the Advanced Practice Provider Clinical Journal of Oncology Nursing articles: A Patient-Specific, Goal-Oriented Exercise Algorithm for Men Receiving Androgen Deprivation Therapy Incorporating Nurse Navigation to Improve Cancer Survivorship Care Plan Delivery Prostate Cancer: Survivorship Care Case Study, Care Plan, and Commentaries The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: A Qualitative Exploration of Prostate Cancer Survivors Experiencing Psychological Distress: Loss of Self, Function, Connection, and Control Identification of Symptom Profiles in Prostate Cancer Survivors Sleep Hygiene Education, ReadiWatch™ Actigraphy, and Telehealth Cognitive Behavioral Training for Insomnia for People With Prostate Cancer Understanding Men's Experiences With Prostate Cancer Stigma: A Qualitative Study Other ONS resources: Late Effects of Cancer Treatment Huddle Card Survivorship Care Plan Huddle Card Survivorship Learning Library American Cancer Society (ACS): Living as a Prostate Cancer Survivor ACS prostate cancer survivorship studies To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Some of the most common late side effects [are] urinary, bowel, and sexual dysfunction issues. For urinary effects, it can include urgency and frequency, some incontinence, or a weak or slow urine stream that frequently bothers the patient after treatment. Bowel effects can happen such as constipation, diarrhea, or inflammation of the rectum, which can lead to bleeding or mucus discharge. And then erectile dysfunction is another side effect that patients with prostate cancer often deal with and have to work with their physicians on, depending on what they want with that function. Fatigue, lymphedema, and skin changes can also occur after treatment." TS 1:40 "If we can catch [prostate cancer] and take care of it at an early stage, overall survival is about 90%. If the disease is localized, it's 99%. If we can take out the prostate, radiate the prostate, we can do something with that—localized, 99% survival rate. If there's regional metastasis, it's about 90%. And if there's distant metastasis, it's about 30% survival." TS 3:55 "Prostate cancer recurs in about 20%–30% of patients within the first five years of initial treatment. ... There's not a lot of research out there that shows what can reduce risk, but what has been shown to be effective is regular exercise, quitting smoking, and eating a healthy diet. ... It's really important for our patients to understand the importance of having follow-up visits so that we can catch a recurrence quickly instead of waiting years down the road. Prostate cancer is usually a slow-growing disease, so if we can pick it up quickly in those revisits, we can start another treatment for the patient." TS 6:00 "Sexuality is not something many people are comfortable discussing, but we really need to talk with patients and let them know that this is normal. It is normal that you may have some sexual dysfunction. It's normal that you may not feel the way you did before. Talk to us about it, let us know where you're at, let us know what your goals are, because there are a lot of things we can do. There are medications we can use for impedance. There are devices and implants available to help the patient to support them and give them whatever their goal is for their sexuality." TS 9:41 "Providing survivorship care plans are important for these patients—something that can be sent off to everyone else that's caring for that patient. You have your primary care physician, urologist, oncologist, the oncology nurse, maybe a navigator, and [others] who are looking into this patient. So, giving that patient a survivor care plan and putting it with their files to include a summary of the treatment received, because most of the time a patient is not going to remember exactly what they received. A suggested schedule for follow-up exams—so again, if a primary care provider is not used to dealing with a patient with prostate cancer, they have something to go off of. A schedule of other tests they may need in the future including screening for other types of cancer. Are they a smoker? Do they need lung screening? Do they need any other screenings related to types of cancers? And then a list of possible late or long-term side effects." TS 15:16 "I think a lot of people know about the long-term sexual effects, but what we don't really talk about is the effect that it has on the patient's self-image. How they define themselves, how they look, their body image, their self-image. It's really important that we continue to discuss it with patients and make them comfortable when discussing their sexuality and their goals for sexuality. They may be having these self-image issues after treatment that they're just not telling us about and that can affect their quality of life." TS 18:38

Réécoutez le FG spécial French Touch History (épisode 1) by DJ Ness du jeudi 18 décembre 2025DJ Ness présente FRENCH TOUCH VINTAGE MIX, un voyage dans la French Touch 1.0 avec des classiques et des raretés.. Au menu : Daft Punk, Bob Sinclar, Superfunk, The Supermen Lovers, Jess & Crabbe, Alex Gopher, Phunky Data, Didier Sinclair, Dax Riders, Demon, Fafa Monteco, Busta Funk, Nicholas, Gran Phabao, Modjo, Sebastien Leger, Cheek, Plaisir de France, Kojak, Dj Bertrand, DDD, Superfunk, Etienne de Crécy, Thomas Bangalter, Buffalo Bunch, Belamour, Stardust, Alan Braxe, Lifelike, DJ Falcon, Das Glow, Fantom

In this explosive episode of Gangland Wire, host Gary Jenkins sits down with actor, entrepreneur, and mob insider Gianni “Johnny” Russo, best known for his unforgettable role as Carlo Rizzi in The Godfather. Russo pulls back the curtain on a lifetime of stories that stretch from Frank Costello and Joe Colombo to Las Vegas skimming, the Vatican Bank, Marilyn Monroe, Jimmy Hoffa, and even Pablo Escobar. Russo discusses his new book, Mafia Secrets: Untold Tales from the Hollywood Godfather, co-written with Michael Benson—an unfiltered account of power, violence, politics, and survival inside the criminal underworld and Hollywood royalty. This is not recycled mythology—this is Gianni Russo's personal version of history from the inside. Whether you believe every word or not, the stories are raw, violent, and utterly fascinating. This episode discusses: The Godfather, The Kennedy assassinations, Vegas skimming, Marilyn Monroe, Jimmy Hoffa, the Chicago Outfit, Pablo Escobar

In the wake of a destructive attack, the crew comes up with a plan...   You do NOT need to listen to Overture to enjoy Anthem! If you have the appetite to listen to both, we recommend starting with Anthem, then going back to listen to Overture!   Gain access to an exclusive campaign, Shroud Over Saltmarsh, over on Patreon: https://legendsofavantris.com/patreon The Crooked Moon, a folk horror supplement for 5e, is available for preorder! Get the Crooked Moon at: https://thecrookedmoon.com/ Watch more D&D adventures in the world of Avantris live on Twitch: https://www.twitch.tv/legendsofavantris Check out our merch store: https://shop.legendsofavantris.com  Join our community on Discord: https://legendsofavantris.com/discord Watch our many campaigns on YouTube: https://legendsofavantris.com/youtube  All other links: https://linktr.ee/legendsofavantris   Watch the full episode here: https://youtu.be/hX9cE_YFGoI?si=s09CS_YTVG5qtloq

Winter is arriving in the UK, so while Saul and Lucy hunker down, don layers and fire up the kettle more frequently than usual, what do their minds turn to in the garden? This is the perfect season for clearance of 2025 growth, for establishing new designs and for de-cluttering stores and greenhouses. Any hours that you can put into the garden now, will reward you hugely come spring and summer, when the jobs mount up. Quick - more tea and biscuits!Many of our listeners will know Martin Fish from his wonderful podcast Pots and Trowels - a gardener very much anchored in the Northern climes of the UK but also a Senior Show judge, Gardens advisor for the RHS and former nursery man. Martin (along with his wide Gill) has been an ever present fixture at many Flower Shows and always has his finger on the pulse of gardening in this country. So we have a good chat about the state of horticulture especially at the Flower Shows and also a little insight into his new garden too.LinkedIn link:Saul WalkerInstagram link:Lucy lucychamberlaingardensIntro and Outro music from https://filmmusic.io"Fireflies and Stardust" by Kevin MacLeod (https://incompetech.com)License: CC BY (http://creativecommons.org/licenses/by/4.0/)Support the show

"I'll go back to the backpack analogy. When your kids come home with a backpack, all of a sudden their homework is not on the desk where it's supposed to be. It's in the kitchen; it kind of spreads all over the place, but it's still in the house. When we give antibody–drug conjugates (ADCs), the chemotherapy does go in, but then it can kind of permeate out of the cell membrane and something right next to it—another cancer cell that might not look exactly like the cancer cell that the chemotherapy was delivered into—is affected and the chemotherapy goes over to that cancer cell and kills it," ONS member Marisha Pasteris, OCN®, office practice nurse in the breast medicine service at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ADCs in metastatic breast cancer. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Gilead and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 378: Considerations for Adolescent and Young Adult Patients With Metastatic Breast Cancer Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 303: Cancer Symptom Management Basics: Ocular Toxicities ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options Communication Case Study: Talking to Patients About Progressive Metastatic Breast Cancer What Is HER2-Low Breast Cancer? ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin-ejfv Fam-trastuzumab deruxtecan-nxki ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Guide to Breast Care for Oncology Nurses Guide to Cancer Immunotherapy (second edition) ONS courses: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care The Association Between Hormone Receptor Status and End-of-Life Care Among Patients With Metastatic Breast Cancer Oncology Nursing Forum article: Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes ONS huddle cards: Altered Body Image Huddle Card Chemotherapy Huddle Card Targeted Therapy Huddle Card Foundations of Antibody–Drug Conjugate Use in Metastatic Breast Cancer: A Case Study ONS Biomarker Database (refine by breast cancer) ONS Breast Cancer Learning Library American Society of Clinical Oncology (ASCO) homepage Drugs@FDA package inserts National Comprehensive Cancer Network homepage Susan G. Komen metastatic breast cancer page To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "What an ADC is doing is taking the antibody and linking it to a cytotoxic chemotherapy with the idea of delivering it directly into the cell. How I explain this to new nurses or patients is a backpack analogy. If we think of it as a HER2 molecule wearing a chemo backpack, it's going to find the HER2 receptor attached to it and then drop the chemotherapy into the cell via the backpack. Similar to how we come home from work, we open the key to our door, we're carrying all of our items, and then we drop our own personal items in our house." TS 2:30 "The reason that so many patients with metastatic breast cancer are able to receive ADC therapy is because they are targeting two very common antibodies that we see in breast cancer. One is HER2 and the other is trophoblast cell surface antigen 2 (TROP2). These are seen across the board. We see these on triple-negative breast cancers, hormone receptor–positive cancers, and HER2-positive breast cancers. And now we have a new way to talk about HER2, which is a HER2-low. ... Recently, we have found that patients who express low levels of HER2 are able to receive ADC therapy, specifically fam-trastuzumab deruxtecan." TS 4:21 "Another [ADC] that has just been approved is datopotamab deruxtecan. This is another ADC that targets the TROP2 receptor on a cancer cell. This one carries a lot of side effects. I mentioned earlier that you need an ophthalmology clearance because there is a lot of ocular toxicity around this one. We see a lot of blepharitis, conjunctivitis, there can be blurred vision. Another thing we monitor on this one is mucositis. In the package insert, there's a recommendation for using ice chips while receiving the treatment. ... Then in the HER2-positive and HER2-low space is the big one, which is fam-trastuzumab deruxtecan. This was approved in 2019 for the HER2-positive patients, then more recently in the HER2-low [patients]. The big [side effect] with this one is interstitial lung disease." TS 10:11 "Interstitial lung disease is an inflammation or a little bit of fibrosis within the lung that causes an impaired exchange between the oxygen and carbon dioxide. This was seen in the clinical trials, specifically around fam-trastuzumab deruxtecan. During the trials, they had a very small percentage, I think it was 1%, that died due to interstitial lung disease. So, this is a very important side effect for us as nurses to be aware of. It typically presents in patients like a dyspnea. A lot of times, it's like, 'Well, I used to be able to walk my kid to the bus stop, but now when I walk there, I feel really short of breath.' Or 'I've had this dry cough for the past couple weeks and I've tried medications, but haven't had that relieved.' So, we really need to be aware of that because early intervention in interstitial lung disease is key." TS 12:57 "ADCs are toxic drugs. They have the benefit of being targeted, but we know that they carry a lot of side effects. ... Their specificity makes them so wonderful and we've seen amazing responses to these drugs. But also, we want patients to be safe. We want to give these drugs safely. So, we have to assess our patients and make sure that this is an appropriate patient to give this therapy to. I think that's an open conversation that clinicians need to have with patients regarding these drugs." TS 18:08

This episode brings together the science, the medicine, and the lived experience behind BRCA mutations.  Emily Goldberg, JScreen's Director of Genetic Counseling Services, breaks down what these mutations are, how they're inherited, and what the actual cancer risks look like. Dr. Melissa Frey, a GYN oncologist at Cornell who works closely with high-risk families, walks us through what happens after someone tests positive — from screening to risk-reducing surgeries to the big conversations around fertility and timing. We also hear from Heather Boussi, who shares her powerful story of living with both BRCA1 and BRCA2 mutations. She talks about diagnosis, surveillance, surgeries, and how this all shaped her family-building decisions. Lastly, we look at what BRCA means for men, how that journey differs, and why PGT can still be an option. If you or someone you love is navigating this, we close with places to turn for support: JScreen, Sharsheret, I Was Supposed To Have A Baby, and Stardust (links below). It's a mix of expertise, honesty, and heart — the kind of conversation so many people wish they had heard earlier, especially when faced with such difficult decisions.  Note: This episode is the 4th of a series of 5 that we are collaborating on with Jscreen in 2025.  Take a look at our previous three episodes here : Episode 157: Introduction to Genetics and Infertility Episode 166: Fragile X Syndrome: A Silent Factor in Infertility Episode 185: It's Not Just Her: Male Factor Fertility and Genetics Uncovered Resources: Genetics and Personalized Cancer Prevention Program Facing Our Risk Empowered (FORCE) Jewish Fertility Foundation Stardust Foundation Sharsheret JScreen More about Emily Goldberg: Emily Goldberg serves as the Director of Genetic Counseling Services at jscreen, where she is dedicated to helping individuals understand and manage their genetic health. With dual bachelor's degrees in biology and psychology from Brandeis University and a master's degree in Human Genetics from Sarah Lawrence College, Ms. Goldberg has been a certified genetic counselor since 2011. Prior to joining jscreen, she worked at Montefiore Medical Center in the Bronx, specializing in prenatal and cancer genetics. In addition to her role at jscreen, Ms. Goldberg is committed to education, serving as an Instructor at the Albert Einstein College of Medicine and adjunct faculty at Sarah Lawrence College, where she teaches and mentors future genetic counselors. Her expertise and dedication make her a key member of the jscreen team. Connect with JScreen: - visit their website here - check out their Instagram   More about Melissa Frey, MD: Dr. Melissa Frey is an Associate Professor of Obstetrics and Gynecology in the division of Gynecologic Oncology and the Director of the Genetics and Personalized Cancer Prevention Program at Weill Cornell Medicine / NewYork Presbyterian Hospital. Dr. Frey's clinical care and research focus on the management of individuals with hereditary cancer syndromes (e.g. BRCA1, BRCA2, Lynch syndrome) and strong family history of breast and gynecologic cancers. She performs gynecologic cancer risk-reducing surgeries and is the principal investigator on several large trials aimed at cancer prevention among high-risk individuals. Dr. Frey has presented her research at national and international meetings and has more than 130 publications in peer-reviewed scientific journals. Connect with Dr. Melissa Frey: - check out her Instagram - view the Genetics and Personalized Cancer Prevention Program website   More about Heather Boussi :  Heather grew up in Westchester, NY and now lives in Englewood, NJ with her husband and three children. Her personal experience with hereditary cancer risk and genetic testing has made her a passionate advocate for awareness, education, and empowerment in women's health. Grounded in faith and family, Heather shares her story to help others approach life's challenges with strength, perspective, and gratitude. Connect with Heather: - check out Heather's Instagram   Connect with us: -Check out our Website -Follow us on Instagram and send us a message -Watch our TikToks -Follow us on Facebook -Watch us on YouTube -Connect with us on LinkedIn

SpaceTime with Stuart Gary - Series 28 Episode 145In this episode of SpaceTime, we explore groundbreaking discoveries that deepen our understanding of the origins of life and the dynamics of our galaxy.Sugars and Stardust: Insights from Asteroid BennuNASA's Osiris Rex mission has returned samples from the asteroid Bennu, revealing the presence of biologically essential sugars, including ribose and glucose, along with a unique gum-like substance never before seen in astromaterials. These findings, published in Nature Geoscience and Nature Astronomy, suggest that the building blocks for life were widespread throughout the early solar system. The discovery of ribose supports the RNA world hypothesis, indicating that RNA might have been the first genetic material. Additionally, the presence of glucose hints at the early energy sources available for life on Earth.Stars Defying the Black HoleAstronomers have observed numerous stars in stable orbits around Sagittarius A, the supermassive black hole at the center of our galaxy. This discovery, reported in Astronomy and Astrophysics, challenges previous assumptions that these objects were merely clouds of dust on a collision course with destruction. Instead, the new data from the ERIS Enhanced Resolution Imager and Spectrograph reveals a dynamic and stable environment around the black hole, providing a unique laboratory for studying interactions between black holes and stars.Martian Mystery Solved?A new radar technique employed by NASA's Mars Reconnaissance Orbiter has cast doubt on the existence of a suspected underground lake beneath the Martian South Pole ice cap. Initial signals that suggested the presence of liquid water have been reinterpreted as possibly being layers of rock and dust. This innovative approach opens new avenues for investigating subsurface resources on Mars, which could have significant implications for future exploration.www.spacetimewithstuartgary.com✍️ Episode ReferencesNature GeoscienceNature AstronomyAstronomy and AstrophysicsGeophysical Research LettersBecome a supporter of this podcast: https://www.spreaker.com/podcast/spacetime-your-guide-to-space-astronomy--2458531/support.

What a Creep Season 31, Episode 4Artie ShawThe lovely and fantastic Simone O. Elias, author of “Old Films, Young Eyes: A Teenage Take on Hollywood's Golden Age,” joins host Sonia Mansfield to talk about Artie Shaw.Artie Shaw played the jazz clarinet and was a big-band leader who reigned supreme as one of the kings of swing with his recordings of "Begin the Beguine," "Lady Be Good," and "Star Dust" in the late 1930s and 40s. He was also an abusive husband, who was married 8 times, ANNNND, he dropped some names at the House of Un-American Activities in the 1950s. What a creep.Sources for this episodeArtieShaw.comEbsco.comThe GuardianThe GuardianThe HairpinNew York TimesNew York TimesNPRSwing and BeyondTimeWikipediaWikipediaBe sure to follow us on social media. But don't follow us too closely … don't be a creep about it!Subscribe to us on Apple PodcastsFacebook: Join the private groupBlueSky Instagram @WhatACreepPodcastVisit our Patreon page: https://www.patreon.com/whatacreepEmail: WhatACreepPod@gmail.com We've got merch here! https://whatacreeppodcast.threadless.com/#Our website is www.whatacreeppodcast.com

Diane and Sean discuss the most charming yet underperforming movie of 2007, Stardust. Episode music is, "Coronation", by Ilan Eshkeri from the OST.-  Our theme song is by Brushy One String-  Artwork by Marlaine LePage-  Why Do We Own This DVD?  Merch available at Teepublic-  Follow the show on social media:-  BlueSky: WhyDoWeOwnThisDVD-  IG: @whydoweownthisdvd- Tumblr: WhyDoWeOwnThisDVD-  Follow Sean's Plants on IG: @lookitmahplants- Watch Sean be bad at video games on TwitchSupport the show

Kelsey recaps her family's epic Thanksgiving week in Orlando, Florida (November 2025), where 11 of them – her family of 5, her sister's family, and her parents – all shared a 7-bedroom house at Evermore Resort. With kids ranging from 4 to 13 years old, they packed in all the fun: Express Passes at Epic Universe, Universal Studios Orlando, and Islands of Adventure, plus lots of downtime enjoying their multi-generational home base at Evermore. Kelsey shares everything you need to know about staying at Evermore Resort, how Express Passes worked for their crew, what the parks were like over Thanksgiving week, and tips to help you decide if this kind of Orlando trip is right for you.If you'd like to share about your trip on the podcast, email me at: kelsey@triptalespodcast.comFollow me on Instagram: https://www.instagram.com/kelsey_gravesFollow me on TikTok: https://www.tiktok.com/@mskelseygravesJoin us in the Trip Tales Podcast Community Facebook Group: https://www.facebook.com/groups/1323687329158879Mentioned in this episode:- Travel planner Courtney Gibson: https://www.instagram.com/pixietravelbycourtney- Flip 7 card game: https://amzlink.to/az0ecfatrzQIM- Evermore Resort- Epic Universe with Express Passes- Ministry of Magic: Battle at the Ministry- Isle of Berk: Hiccup's Wing Gliders, Mead Hall for lunch- Celestial Park: Stardust Racers, Celestial Carousel- Super Mario Land- Dark Universe: Monsters Unchained, Curse of the Werewolf, Burning Blade Tavern- Helios Grand Hotel- Universal Studios Florida and Islands of Adventure: Butter Beer, Seuss Landing, VelociCoaster, Mythos Restaurant, Hogwarts Express, Universal's Holiday ParadeTrip Tales is a travel podcast sharing real vacation stories and trip itineraries for family travel, couples getaways, cruises, and all-inclusive resorts. Popular episodes feature destinations like Marco Island Florida, Costa Rica with kids, Disney Cruise Line, Disney Aulani in Hawaii, Beaches Turks & Caicos, Park City ski trips, Aruba, Italy, Ireland, Portugal's Azores, New York City, Alaska cruises, and U.S. National Parks. Listeners get real travel tips, itinerary recommendations, hotel reviews, restaurant recommendations, and inspiration for planning their next vacation, especially when traveling with kids.

Winter is arriving in the UK, so while Saul and Lucy hunker down, don layers and fire up the kettle more frequently than usual, what do their minds turn to in the garden? This is the perfect season for clearance of 2025 growth, for establishing new designs and for de-cluttering stores and greenhouses. Any hours that you can put into the garden now, will reward you hugely come spring and summer, when the jobs mount up. Quick - more tea and biscuits!Podcast listeners have turned Lucy's head from the garden this week, as talk of her favourite biscuit reach a peak. But, she's regained her focus by making Christmas wreaths and playing with her new toy: the Scheppach RS400 compost sieve. Saul, meanwhile has been taking a spin in the Stonelands' 4x4, to source a Christmas tree for the family. He's also been attempting to extract himself physically and emotionally from the Stonelands estate - a process that is taking him longer than anticipated. Wisley glasshouse staff, watch out...LinkedIn link:Saul WalkerInstagram link:Lucy lucychamberlaingardensIntro and Outro music from https://filmmusic.io"Fireflies and Stardust" by Kevin MacLeod (https://incompetech.com)License: CC BY (http://creativecommons.org/licenses/by/4.0/)Support the show

"Working as an oncology infusion nurse, being oncology certified, attending chapter meetings, going to ONS Congress® has really taught me plenty. But being an oncology patient taught me way more. I know firsthand the fears 'you have cancer' brings. Then going through further testing, CT scans, MRIs, genetics, the whole preparation for surgery was something I never considered when I treated a breast cancer patient," ONS member Catherine Parsons, RN, OCN®, told Valerie Burger, MA, MS, RN, OCN®, CPN, member of the ONS 50th anniversary planning committee, during a conversation about her experience being an oncology nurse and cancer survivor. Burger spoke with Parsons and ONS members Margaret Hopkins, MSN, RN, OCN®, HNB-BC, and Afton Dickerson, MSN, AGACNP-BCP, CBCN®, AOCNP®, CGRA, about how cancer survivorship has shaped their careers as oncology nurses and personal lives. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD.  ONS Podcast™ episodes: 50th anniversary series Episode 385: ONS 50th Anniversary: Evolution of Cancer Survivorship Episode 263: Oncology Nursing Storytelling: Renewal Episode 253: The Ethics of Caring for People You Know Personally Episode 187: The Critical Need for Well-Being and Resiliency and How to Practice Episode 91: The Seasons of Survivorship ONS Voice articles: Being a Patient Taught Me How to Be a Better Oncology Nurse by Margaret Hopkins Sharing Our Stories Supports, Celebrates, and Advances the Nursing Profession Our Unified Voices Can Improve Cancer Survivorship Care Why I Truly Understand How Our Patients Hold Onto Hope ONS book: Oncology Nurse Navigation: Delivering Patient-Centered Care Across the Continuum (third edition) ONS course: Essentials in Survivorship Care for the Advanced Practice Provider ONS Nurse Well-Being Learning Library ONS Huddle Cards: Coping Moral Resilience Survivorship Care Connie Henke Yarbro Oncology Nursing History Center To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Parsons: "I thought I knew cancer. I thought I knew the treatment. I thought I knew the side effects. There's so much I didn't know. There's so much behind the scenes before a patient comes and sits in my chair. The stuff that they go through I now can understand. It surprised me how much I didn't know." TS 11:39 Hopkins: "I had been thinking I'm going to be that hero, that I can go to work. I work at night, get 8 am radiation appointments, and go home and go to sleep and wake up and go to work again because everyone said, 'Oh, it's not that bad. Radiation will be okay. You can work.' … But the real challenge for me was I didn't know how to be a patient and a nurse at the same time. And my first radiation treatment, I go in there, and I change into the gown, and then I started cleaning up because I was getting treatment done at the hospital where I worked, and were taught if you see a mess, you clean it. So I was acting like a nurse. And I almost wanted to go help the other patients, but I couldn't because I had to focus on healing." TS 15:36 Dickerson: "What made the difference for me were the nurses who didn't just treat my illness. They treated me as a whole person—my emotions, my feelings. They made me smile. They would hold my hand or just take a moment to really ask, 'Hey, how are you?' And those small, little gestures made me feel worthy, made me feel like a human. I always tell nurses it's not just about the chemo; it's about the connection. Sometimes your presence is the most healing thing that you can offer to your patient." TS 30:52

This week, hosts Tom Rivett Carnac and Paul Dickenson delve into the rapidly emerging - and faintly surreal - world of solar geoengineering. Politico journalist Karl Mathiesen joins us to unpack his investigation into Stardust, a VC-backed startup claiming it's ready to spray particles into the stratosphere. Karl explains why this technology is suddenly attracting serious money, why scientists still have major questions about safety and side effects, and how in some places, the global regulatory landscape is almost nonexistent.And from technological disruption to political stability, former New Zealand Prime Minister Jacinda Ardern, reflects on the leadership we need. She's unflinchingly honest about why so many politicians still choose “fear and blame” over long-term action, and why climate remains New Zealand's “nuclear-free moment.” A test of political character as much as policy. Her argument is hopeful: people, she insists, are ahead of their politics.As we march towards the end of 2025, these conversations map the terrain of 2026: technologies racing ahead, governance lagging behind, and a public increasingly hungry for leaders willing to act with integrity. If you want to understand where the climate fight is really heading this episode is essential.Learn more:

The Rhapsody crew and their new friend, Ko, pursue a lead...   You do NOT need to listen to Overture to enjoy Anthem! If you have the appetite to listen to both, we recommend starting with Anthem, then going back to listen to Overture!   Gain access to an exclusive campaign, Shroud Over Saltmarsh, over on Patreon: https://legendsofavantris.com/patreon The Crooked Moon, a folk horror supplement for 5e, is available for preorder! Get the Crooked Moon at: https://thecrookedmoon.com/ Watch more D&D adventures in the world of Avantris live on Twitch: https://www.twitch.tv/legendsofavantris Check out our merch store: https://shop.legendsofavantris.com  Join our community on Discord: https://legendsofavantris.com/discord Watch our many campaigns on YouTube: https://legendsofavantris.com/youtube  All other links: https://linktr.ee/legendsofavantris   Watch the full episode here: https://youtu.be/LdmZ17y11MY?si=h-HWL737dDx6HcGO

Autumn is here on the Talking Heads podcast - as the last vestiges of Summer in the garden dodge the wet and windy weather while trying to give the last hurrah before that inevitable but pleasantly seasonable slide into the hibernation of winter. But gardeners never sleep so Lucy and Saul are still out and about in their plots plying the horticultural trade they both love. So join them both for more horti-waffle and insights into the life of the modern, professional gardener.Leaves, frost and rain...that's been this Autumn summed up...so not much gardening talk on todays podcast but instead two pieces of huge news in Saul and Lucy's lives. After 10 years of early mornings, tractor breakdowns and the occasional piece of cake Saul is leaving Stonelands to take up a new job role at Plant Heritage, while Lucy becomes a two-time winner of the Garden Media Guilds Practical Journalist of the Year! You would have thought the pair were good at their jobs...well lets find out..Instagram link:Lucy lucychamberlaingardensLinkedIn link:Saul WalkerIntro and Outro music from https://filmmusic.io"Fireflies and Stardust" by Kevin MacLeod (https://incompetech.com)License: CC BY (http://creativecommons.org/licenses/by/4.0/)Support the show

"Antibody–drug conjugates (ADCs) have three basic parts: the antibody part, the cytotoxic chemo, and the linker that connects the two. First, the antibody part binds to the target on the surface of the cell. Antibodies can be designed to bind to proteins with a very high level of specificity. That's what gives it the targeted portion. Then the whole thing gets taken up by the cell and broken down, which releases the chemotherapy part. Some sources will call this the 'payload' or the 'warhead.'  That's the part that's attached to the 'heat-seeking' part, and that's what causes the cell death," Kenneth Tham, PharmD, BCOP, clinical pharmacist in general oncology at the University of Washington Medicine and Fred Hutchinson Cancer Center in Seattle, WA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about antibody–drug conjugates. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 28, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the mechanism of action of antibody–drug conjugates. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 303: Cancer Symptom Management Basics: Ocular Toxicities Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Antibody–Drug Conjugates Join the Best of Two Worlds Into One New Treatment Nursing Management of Adverse Events From Enfortumab Vedotin Therapy for Urothelial Cancer Oncology Nurses' Role in Translating Biomarker Testing Results The Pharmacist's Role in Combination Cancer Treatments ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin Fam-trastuzumab deruxtecan-nxki ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Other ONS resources: Antineoplastic Administration Huddle Card Biomarker Database Chemotherapy Huddle Card Monoclonal Antibodies Huddle Card Association of Cancer Care Centers (ACCC) antibody–drug conjugates page Drugs@FDA Hematology/Oncology Pharmacy Association (HOPA) National Cancer Institute cancer drugs page Network for Collaborative Oncology Development and Advancement (NCODA) clinical resource library ACCC/HOPA/NCODA/ONS Patient Education Sheets website To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The mechanism of action of the chemo itself depends on what agent or what 'warhead' is attached. Generally, [ADCs] have some kind of cytotoxic mechanism related to many of the chemotherapies that we use in practice, without attachment to the antibody. Some of them can be microtubule inhibitors, vinca alkaloids like vincristine. Some of them can be topoisomerase I (TOP1) inhibitors like irinotecan. Some can be alkylating agents that cause DNA breaks. So, again, looking back at the arsenal we have of cytotoxic chemo, these can all be incorporated into the ADCs." TS 5:54 "I want to talk about a case where the biomarker is being tested, but the biomarker isn't the target that you're looking for. One good case of this is a newer agent that was approved called datopotamab deruxtecan. The datopotamab portion is specific to a target called 'trophoblast cell surface antigen 2' (TROP2), which is expressed on the surface of many epithelial cancers. This agent was first approved in hormone receptor-positive, HER2-negative breast cancer, and received accelerated approval in patients with non-small cell lung cancer (NSCLC) with an EGFR mutation. ... The antibody looks for a target, TROP2. But in both of these cases—in the breast cancer and the NSCLC—you're testing for expression of different mutations or lack thereof. You're not looking for expression of TROP2. There's more research that needs to be done about the relationship between TROP2 expression and the presence or absence of these other biomarkers, but until we know more, we're actually testing for biomarkers that aren't the target of the ADC." TS 10:22 "There are common adverse advents to antibodies and chemo in general. Because we have both of these components, we want to watch out for the adverse effects of both of them. Antibodies, as with most proteins, can trigger an immune response or an infusion reaction. So, many ADCs can also cause hypersensitivity or infusion reactions. The rates of that are really variable and depend on the actual antibodies themselves. Then you have the cytotoxic component, the chemotherapy component, which has its own characteristic side effects. So, if we think of general chemo side effects—fatigue, nausea, bone marrow suppression, alopecia—these can [occur] with a lot of ADCs as well." TS 15:34 "The rate of ocular toxicity in [mirvetuximab soravtansine] is quite high. The manufacturer reports that this can occur in up to 60% of patients. With rates so high, the manufacturer recommends a preventive strategy. For this particular agent, [they] recommend patients have required eyecare. ... This ocular toxicity is something we do see in other ADCs that don't have the same target and don't necessarily have the same payload component. For example, tisotumab vedotin and again, datopotamab deruxtecan, can both cause ocular toxicities and both would have required ocular supportive care." TS 20:08 "Overall, I feel like the future is incredibly bright for these agents. There have only been around a dozen therapies approved by the U.S. Food and Drug Administration (FDA) despite this idea—the first agent came out in 2000. So, 25 years later, there are only around a dozen FDA-approved treatments. But there are so many more that are coming through the pipeline. And as we're discovering more biomarkers and developing more specialized antibodies, it's only natural that more ADCs will follow." TS 26:50

Songs include: Stardust by Artie Shaw, Swinging On a Star by Bing Crosby, The Second Star to the Right by Doris Day, Stars Fell on Alabama by Guy Lombardo and The Stars and Stripes Forever by Frankie Laine.

"Any time the patient hears the word 'cancer,' they shut down a little bit, right? They may not hear everything that the oncologist or urologist, or whoever is talking to them about their treatment options, is saying. The oncology nurse is a great person to sit down with the patient and go over the information with them at a level they can understand a little bit more. To go over all the treatment options presented by the physician, and again, make sure that we understand their goals of care," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer treatment considerations for nurses.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 21, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 373: Biomarker Testing in Prostate Cancer Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 208: How to Have Fertility Preservation Conversations With Your Patients Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: Communication Models Help Nurses Confidently Address Sexual Concerns in Patients With Cancer Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Nurses Are Key to Patients Navigating Genitourinary Cancers Sexual Considerations for Patients With Cancer The Case of the Genomics-Guided Care for Prostate Cancer ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition) Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) Clinical Journal of Oncology Nursing articles: Brachytherapy: Increased Use in Patients With Intermediate- and High-Risk Prostate Cancers Physical Activity: A Feasibility Study on Exercise in Men Newly Diagnosed With Prostate Cancer The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: An Exploratory Study of Cognitive Function and Central Adiposity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer ONS Guidelines™ for Cancer Treatment–Related Hot Flashes in Women With Breast Cancer and Men With Prostate Cancer Other ONS resources: Biomarker Database (refine by prostate cancer) Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Brachytherapy Huddle Card External Beam Radiation Huddle Card Hormone Therapy Huddle Card Luteinizing Hormone-Releasing Hormone Antagonist Huddle Card Sexuality Huddle Card American Cancer Society prostate cancer page National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "I think it's important to note that urologists are usually the ones that are doing the diagnosis of prostate cancer and really start that staging of prostate cancer. And the medical oncologists usually are not consulted until the patient is at a greater stage of prostate cancer. I find that it's important to state because a lot of our patients start with urologists, and by the time they've come to us, they're a lot further staged. But once a prostate cancer has been suspected, the patient needs to be staged for the extent of disease prior to that physician making any treatment recommendations. The staging includes doing a core biopsy of the prostate gland. During this core biopsy, they take multiple different cores at different areas throughout the prostate to really look to see what the cancer looks like." TS 1:46 "[For] the very low- and low-risk group, the most common [treatment] is active surveillance. ... Patients can be offered other options such as radiation therapy or surgery if they're not happy with active surveillance. ... The intermediate-risk group has favorable and unfavorable [status]. So, if they're a favorable, their Gleason score is usually a bit lower, things are not as advanced. These patients are offered active surveillance and then either radical prostatectomy with possible removal of lymph nodes or radiation—external beam or brachytherapy. If a patient has unfavorable intermediate risk, they are offered radical prostatectomy with removal of lymph nodes, external radiation therapy plus hormone therapy, or external radiation with brachytherapy. All three of these are offered to patients, although most frequently we see that our patients are taken in for radical prostatectomy. For the high- or very high-risk [group], patients are offered radiation therapy with hormone therapy, typically for one to three years. And then radical prostatectomy with removal of lymph nodes could also be offered for those patients." TS 7:55 "Radiation can play a role in any risk group depending on the patient's preference. ... The types of radiation that we use are external beam, brachytherapy, which is an internal therapy, and radiopharmaceuticals, [which are] more for advanced cancer, but we are seeing them used in prostate [cancer] as well. External beam radiation focuses on the tumor and any metastasis we may have with the tumor. It can be used in any risk [group] and for recurrence if radiation has not been done previously. If a patient has already been radiated to the pelvic area or to the prostate, radiation is usually not given again because we don't want to damage the patient any further. Brachytherapy is when we put radioactive pellets directly into the prostate. For early-stage prostate cancer, this can be given alone. And for patients who have a higher risk of the cancer growing outside the prostate, it can be given in combination with external beam radiation. It's important to note with brachytherapy, it cannot be used on patients who've had a transurethral resection of the prostate or any urinary problems. And if the patient has a large prostate, they may have to be on some hormone therapy prior to brachytherapy, just to shrink that prostate down a little bit to get the best effect. ... Radiopharmaceuticals treat the prostate-specific membrane antigen." TS 11:05 "The side effects of surgery are usually what deter the patient from wanting surgery. The first one is urinary incontinence. A lot of times, a patient has a lot of urinary incontinence after they have surgery. The other one is erectile dysfunction. A lot of patients may not want to have erectile dysfunction. Or, if having an erection is important to the patient, they may not want to have surgery to damage that. In this day and age, physicians have gotten a lot better at doing nerve-sparing surgeries. And so they really do try to do that so that the patient does not have any issues with erectile dysfunction after surgery. But [depending on] the extent of the cancer where it's growing around those nerves or there are other things going on, they may not be able to save those nerves." TS 15:26 "Luteinizing hormone-releasing hormone, or LHRH antagonists or analogs, lower the amount of testosterone made by the testicles. We're trying to stop those hormones from growing to prevent the cancer. ... When we lower the testosterone very quickly, there can be a lot more side effects. But if we lower it a little bit less, we can maybe help prevent some of them. The side effects are important. When I was writing this up, I was thinking, 'Okay, this is basically what women go through when they go through menopause.' We're decreasing the estrogen. We're now decreasing the testosterone. So, the patients can have reduced or absent sexual desire, they can have gynecomastia, hot flashes, osteopenia, anemia, decreased mental sharpness, loss of muscle mass, weight gain, and fatigue." TS 17:50 "What we all need to remember is that no patient is the same. They may not have the same goals for treatment as the physicians or the nurses want for the patient. We talked about surgery as the most common treatment modality that's presented to patients, but it's not necessarily the option that they want. It's really important for healthcare professionals to understand their biases before talking to the patients and the family. It's also important to remember that not all patients are in heterosexual relationships, so we need to explain recovery after treatment to meet the needs of our patients and their sexual relationships, which is sometimes hard for us. But remembering that—especially gay men—they may not have the same recovery period as a heterosexual male when it comes to sexual relationships. So, making sure that we have those frank conversations with our patients and really check our biases prior to going in and talking with them." TS 27:16

Today's Song of the Day is “Copycats” by hip-hop artist Danny Brown, featuring underscores. The song comes from Brown's new album, Stardust, which released November 7 on Warp Records.

In the second half of How To!'s wide-ranging conversation about home improvement, gender, sexuality, and much more, journalist Sam Sanders and author Mercury Stardust (aka The Trans Handy Ma'am) talk with co-host Carvell Wallace about a truly daunting idea: skipping the contractors—and doing the work yourself. This episode is available to Slate Plus members now. Non-members will be able to listen on Nov. 11, 2025. If you missed the first half of this conversation, check out How To Talk to Contractors (With Sam Sanders and Mercury Stardust). Mercury's latest book is Safe and Sound: A Renter-Friendly Guide to Home Repair. And, check out the latest episodes of The Sam Sanders Show. Do you have a problem that needs solving? Send us a note at howto@slate.com or leave us a voicemail at 646-495-4001 and we might have you on the show. Subscribe for free on Apple, Spotify or wherever you listen. The show is produced by Rosemary Belson and Sophie Summergrad. Our technical director is Merritt Jacob and our supervising producer is Joel Meyer. Get more of How To! with Slate Plus! Join for exclusive bonus episodes of How To! and ad-free listening on all your favorite Slate podcasts. Subscribe from the How To! show page on Apple Podcasts or Spotify. Or, visit slate.com/howtoplus for access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices

In the second half of How To!'s wide-ranging conversation about home improvement, gender, sexuality, and much more, journalist Sam Sanders and author Mercury Stardust (aka The Trans Handy Ma'am) talk with co-host Carvell Wallace about a truly daunting idea: skipping the contractors—and doing the work yourself. This episode is available to Slate Plus members now. Non-members will be able to listen on Nov. 11, 2025. If you missed the first half of this conversation, check out How To Talk to Contractors (With Sam Sanders and Mercury Stardust). Mercury's latest book is Safe and Sound: A Renter-Friendly Guide to Home Repair. And, check out the latest episodes of The Sam Sanders Show. Do you have a problem that needs solving? Send us a note at howto@slate.com or leave us a voicemail at 646-495-4001 and we might have you on the show. Subscribe for free on Apple, Spotify or wherever you listen. The show is produced by Rosemary Belson and Sophie Summergrad. Our technical director is Merritt Jacob and our supervising producer is Joel Meyer. Get more of How To! with Slate Plus! Join for exclusive bonus episodes of How To! and ad-free listening on all your favorite Slate podcasts. Subscribe from the How To! show page on Apple Podcasts or Spotify. Or, visit slate.com/howtoplus for access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices

In the second half of How To!'s wide-ranging conversation about home improvement, gender, sexuality, and much more, journalist Sam Sanders and author Mercury Stardust (aka The Trans Handy Ma'am) talk with co-host Carvell Wallace about a truly daunting idea: skipping the contractors—and doing the work yourself. This episode is available to Slate Plus members now. Non-members will be able to listen on Nov. 11, 2025. If you missed the first half of this conversation, check out How To Talk to Contractors (With Sam Sanders and Mercury Stardust). Mercury's latest book is Safe and Sound: A Renter-Friendly Guide to Home Repair. And, check out the latest episodes of The Sam Sanders Show. Do you have a problem that needs solving? Send us a note at howto@slate.com or leave us a voicemail at 646-495-4001 and we might have you on the show. Subscribe for free on Apple, Spotify or wherever you listen. The show is produced by Rosemary Belson and Sophie Summergrad. Our technical director is Merritt Jacob and our supervising producer is Joel Meyer. Get more of How To! with Slate Plus! Join for exclusive bonus episodes of How To! and ad-free listening on all your favorite Slate podcasts. Subscribe from the How To! show page on Apple Podcasts or Spotify. Or, visit slate.com/howtoplus for access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices

SPONSORS: - Sign up for a $1 per month trial period at https://shopify.com/dannyb - Our listeners get 10% off their first month at https://betterhelp.com/dannybrown Danny Brown is locked in this week—he can't stop playing NBA 2K, he's linking up with JuiceLand to make his own smoothie, and he's got plenty to say about the “depressed generation,” performative masculinity, and staying mentally strong. Danny talks about the excitement of dropping his new album, shares his thoughts on chasing AI money, and even offers to teach you how to rap. It's classic Danny: chaotic, funny, and full of unexpected wisdom. Don't sleep—Danny's new album Stardust is out now on all platforms.

Sam Sanders is many things: journalist, podcaster, pop-culture obsessive, and a familiar voice from public radio. He's also ”quite possibly the world's most hesitant homeowner.” Sam wants to fix up the house he recently bought, but three things are holding him back: First, he doesn't have a clue where to start. Second, he's not very handy. And third, he's intimidated by the thought of talking with contractors (who might discover the first two things about him). In the first episode of a two-part series, Carvell Wallace brings on home improvement expert and bestselling author Mercury Stardust (aka The Trans Handy Ma'am) to guide Sam in conquering his fears. Mercury's latest book is Safe and Sound: A Renter-Friendly Guide to Home Repair. Check out the latest episodes of The Sam Sanders Show. Next week: How To Take Charge of Home Repair (with Sam Sanders and Mercury Stardust). Can't wait for part 2? Slate Plus members can listen to that episode in their feeds right now!  Do you have a problem that needs solving? Send us a note at howto@slate.com or leave us a voicemail at 646-495-4001 and we might have you on the show. Subscribe for free on Apple, Spotify or wherever you listen. The show is produced by Rosemary Belson and Sophie Summergrad. Our technical director is Merritt Jacob and our supervising producer is Joel Meyer. Get more of How To! with Slate Plus! Join for exclusive bonus episodes of How To! and ad-free listening on all your favorite Slate podcasts. Subscribe from the How To! show page on Apple Podcasts or Spotify. Or, visit slate.com/howtoplus for access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices

Sam Sanders is many things: journalist, podcaster, pop-culture obsessive, and a familiar voice from public radio. He's also ”quite possibly the world's most hesitant homeowner.” Sam wants to fix up the house he recently bought, but three things are holding him back: First, he doesn't have a clue where to start. Second, he's not very handy. And third, he's intimidated by the thought of talking with contractors (who might discover the first two things about him). In the first episode of a two-part series, Carvell Wallace brings on home improvement expert and bestselling author Mercury Stardust (aka The Trans Handy Ma'am) to guide Sam in conquering his fears. Mercury's latest book is Safe and Sound: A Renter-Friendly Guide to Home Repair. Check out the latest episodes of The Sam Sanders Show. Next week: How To Take Charge of Home Repair (with Sam Sanders and Mercury Stardust). Can't wait for part 2? Slate Plus members can listen to that episode in their feeds right now!  Do you have a problem that needs solving? Send us a note at howto@slate.com or leave us a voicemail at 646-495-4001 and we might have you on the show. Subscribe for free on Apple, Spotify or wherever you listen. The show is produced by Rosemary Belson and Sophie Summergrad. Our technical director is Merritt Jacob and our supervising producer is Joel Meyer. Get more of How To! with Slate Plus! Join for exclusive bonus episodes of How To! and ad-free listening on all your favorite Slate podcasts. Subscribe from the How To! show page on Apple Podcasts or Spotify. Or, visit slate.com/howtoplus for access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices

Sam Sanders is many things: journalist, podcaster, pop-culture obsessive, and a familiar voice from public radio. He's also ”quite possibly the world's most hesitant homeowner.” Sam wants to fix up the house he recently bought, but three things are holding him back: First, he doesn't have a clue where to start. Second, he's not very handy. And third, he's intimidated by the thought of talking with contractors (who might discover the first two things about him). In the first episode of a two-part series, Carvell Wallace brings on home improvement expert and bestselling author Mercury Stardust (aka The Trans Handy Ma'am) to guide Sam in conquering his fears. Mercury's latest book is Safe and Sound: A Renter-Friendly Guide to Home Repair. Check out the latest episodes of The Sam Sanders Show. Next week: How To Take Charge of Home Repair (with Sam Sanders and Mercury Stardust). Can't wait for part 2? Slate Plus members can listen to that episode in their feeds right now!  Do you have a problem that needs solving? Send us a note at howto@slate.com or leave us a voicemail at 646-495-4001 and we might have you on the show. Subscribe for free on Apple, Spotify or wherever you listen. The show is produced by Rosemary Belson and Sophie Summergrad. Our technical director is Merritt Jacob and our supervising producer is Joel Meyer. Get more of How To! with Slate Plus! Join for exclusive bonus episodes of How To! and ad-free listening on all your favorite Slate podcasts. Subscribe from the How To! show page on Apple Podcasts or Spotify. Or, visit slate.com/howtoplus for access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices